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ABSTRACT

Potluri, Keerti. M.S. Department of Biochemistry and Molecular Biology, Wright State
University, 2015. ENTITLED Improving DNA quality using FFPE tissues for Array

Comparative Genomic Hybridization to find Single Nucleotide Polymorphisms (SNPs) in
Melanoma.

Important classes of benign and malignant neoplasms are composed of melanocytic cells
which produce a pigment called melanin. Benign nevi, which are non-malignant
melanocytic lesions, can sometimes give rise to malignant melanoma. Melanoma can be a
lethal melanocytic neoplasm, a deadly and aggressive form of skin cancer. Finding
prognostic or diagnostic markers can be very useful to reduce the deaths caused by
melanoma. Array Comparative Genomic Hybridization (aCGH), a cytogenetic technique,
analyzes the whole genome or chromosome for detecting genetic aberrations/variations
such as single nucleotide polymorphisms (SNPs) in a cancer. formalin fixed paraffin
embedded FFPE tissues are usually taken from suspected tumor tissues, fixed with
formalin to preserve the protein and cytoskeletal structure and embedded in paraffin wax
so that they can be cut and used for pathological diagnosis. These specimens are the
starting material for extracting the DNA, but it can be quite challenging for getting DNA
of good quality. Here we compared 27 samples extracted from FFPE tissues with three
different extraction methods: phenol-chloroform isoamyl alcohol, Qiagen QIAamp FFPE
iii

kit, and adaptive focused acoustics (AFA) to see whether the method will have any effect
on the DNA quality in the samples. We found that the AFA method showed better quality
control (QC) results than other methods, where AFA showed increased amplicon length
and decreased RAPD PCR failure rate. These were successfully hybridized to the
microarrays and the data compared between methods. A total of 42 melanocytic nevi and
21 benign nevi were analyzed by aCGH. We found some novel SNPs and the genes
associated with them, these genes are already shown to be involved in melanoma as well
as in benign nevi. So, these findings can help to see whether the SNPs from benign nevi
are predisposing to melanoma or if the SNPs themselves are causing the melanoma and
help

identify

potential

therapeutic

iv

targets.

HYPOTHESIS

The hypothesis of the project is that the quality of the DNA does have an effect on how
successfully the samples can hybridize onto array CGH microarrays. Therefore,
improving the quality of the DNA will improve the aCGH data to efficiently find SNPs
that cause/predispose to malignant melanoma, which can be useful for finding
prognostic/diagnostic markers.

PROJECT AIMS

1. Optimize the quality of extracted genomic DNA from formalin-fixed paraffin
embedded tissues for DNA fragment length, yield, and PCR performance.
2. Improve the performance of SNP 6.0 microarrays for FFPE DNA and generate
raw array data.
3. Detect the novel SNPs that predispose to malignant melanoma.
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I.INTRODUCTION AND BACKGROUND

Melanoma is one type of skin cancer that is serious. This cancer occurs in melanocyte
cells which are present in the skin like uvea of the eye and also it can occur in mouth,
anal or genital areas and other organs inside the body like the intestines. The melanocytes
are present in one of the layers of skin called epidermis where they produce a pigment
called “melanin”. This melanin gives color to the skin based on how much is present in
the skin, the more the melanin the darker the skin will be. Of all the skin cancers
melanoma is least common (%2), yet it is the cause of most skin cancer-related deaths
[2]. According to the American Cancer Society, in 2015 approximately 74,000 cases will
be diagnosed in the US and approximately 10,000 people will die from this cancer.
Benign nevi which are noncancerous (moles) and non-metastatic when exposed to risk
factors like UV light sometimes develop into cancerous tumors and spreads to the lymph
nodes, blood vessels and finally to other organs like the lungs, brain etc. and become
metastasized. It is a rare cancer and curable if detected in the early stages [3] but is
deadly once metastasized everywhere. The 5 year survival rate shows that depending on
the stage of the cancer when diagnosed, it can be as high as 98% when it does not spread
, it decreases to 67% if it spreads to other lymph nodes and to less than 15% if it spreads
to other organs [2]. People with risk factors like red hair, fair skin and blue eyes are at
increased risk of melanoma [4] but these factors are only some of the genetic risk factors
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associated with melanoma. Melanocytes can give rise to both benign melanocytic nevi
and malignant melanoma. A high risk of melanoma is found in if the people having a
family history of the disease [5]even though it is otherwise rare. Some studies have
shown that those who had familial melanoma, and so many benign melanocytic nevi
there is strong chance that the nevi can give rise to the melanoma[6-9].
Early diagnosis of melanoma is very important for treatment. Histopathologic study of
skin biopsies by dermatopathologists is considered as the standard approach to diagnose
skin lesions with the help of microscope [10]. Cellular anatomy of a tumor revealed by
Hematoxylin and Eosin (H&E) staining which is one of the most widely used standard
method to diagnose the suspected tumors. This staining method helps in showing staging
and grading of the tumor taken from the skin biopsies. These are developed to determine
the treatment and prognosis of malignant neoplasms. Staging tells the condition of cancer
depending on whether the size or extension of invasion is large or not, if the invasion is
spread to lymph nodes or not and tells the presence/absence of distant metastases. Stage 0
shows that the melanoma is in situ, stage I, II and III show that the tumor size is large and
spread to other organs like lymph nodes and/or nearby organs to primary tumor site, stage
IIII shows that the cancer has already spread to distant organs [11] On the other hand,
grading is dependent upon the microscopic observation of the malignant neoplasms in
H&E staining. It tells about the abnormality of tumor tissues and look under microscope.
The higher the grading the less differentiation of cells and the worse the behavior of
malignant neoplasms and vice versa, since benign neoplasms are well differentiated and
differentiated cells have the resemblance of the original cells [12]. However,
histopathology does not show the molecular changes. Since it is sometimes difficult to
2

differentiate benign nevi from malignant melanoma, because some melanocytic tumors
share common histopathological features that are overlapping. Some benign melanocytic
nevi, because of secondary changes, show abnormal characteristics that are mostly
associated with the melanoma diagnosis. Therefore the histopathologic diagnosis of these
tumors can be a challenge [13]. The histopathologic examination is sometimes not
enough to make the diagnostic decisions. Several studies reported the uncertainty and
discordance in diagnosing melanoma from benign nevi among the dermatopathologists
who are experts in this area [13-19]. The ambiguity of melanoma can lead to
misdiagnosis. Over diagnosis makes more stress, unnecessary surgeries and cost of
medical insurance. On the other hand, under diagnosis can result in negligence of the
disease[3] and can be deadly but curable if detected in the early stages. Because of this,
molecular diagnostic techniques have become ancillary tools to aid diagnosis of
melanocytic lesions. These techniques have shown to be useful in identifying the
melanocytic lesions and the presence of melanoma.
BRAF is a serine/threonine protein kinase involved in the MEK/ERK pathway. Mutations
in this protein; BRAF V600E (about 80%) and BRAF V600K (about 5-30%) are most
prevalent in melanoma [20]. Vemurafenib is an inhibitor of mutant BRAF activity.
Patients in late stage melanoma when treated with Vemurafenib have improved survival
chances [21]. These mutations can occur later in life as oncogene, causing cancer and is
seen in both melanoma and rarely in nevi. To know the existence of these mutations,
histopathological observations are not enough. Molecular diagnostic methods like
Immunohistochemistry (IHC)

are available as adjunct techniques for diagnosing

melanoma by looking into melanocytic lesions [22] [23, 24] by looking at the protein
3

expression level. Some of the markers used for IHC include: S-100, HMB-45, Mitf,
Melan-A, and tyrosinase for diagnosing melanoma [25] and also Ki-67 which is used as
mitotic index to determine the stage of the cell tumor [26]. S-100 protein is a calcium
binding protein and it has association with malignant melanoma because the higher
expression of it leads to cancer cell proliferation, differentiation, tumor metastases, cell
invasion, cell growth and apoptosis [27] S100 protein monoclonal antibody thus can help
in diagnosing melanoma from tumors by reacting with the antigens in the melanocytic
tumors with doubtful histological origin and tells whether the presence of tumors is in
lymph nodes or other tissues [27] [28]. HMB-45 is a monoclonal antibody that reacts to
antigens in the melanocytic tumors only. It has a good specificity for identifying
malignant melanomas thus avoiding poor diagnosis [29, 30]. Mitf is a transcription factor
involves in the regulation of pathways of cells like melanocytes, it regulates the
production of melanin in melanocytes. Any mutation in Mitf leads to melanoma [31] .
Recently Mitf immunohistochemical stain is used in identifying metastatic melanoma
effectively [32]. Melan-A is a protein antigen found in the melanocytes. The melan-A
marker is found to be useful in diagnosing melanoma [33] [34]. Ki-67 is a protein
involved in cell proliferation and the marker can help in identifying the cell stage
especially during mitosis to determine the growth of the tumor [26]. But all these markers
still lack a certain group of lesions indeterminate even to expert pathologists.
Additionally, cytogenetic techniques have emerged to diagnose melanocytic lesions.
Fluorescence in situ hybridization (FISH) is one of these techniques that have gained use
in melanoma diagnostics [10, 35-37]. FISH recently has a set of new four probes
targeting 6p25 (RREB1), 6q23 (MYB), 11q13 (CCND1), and centromere 6 (CEP6) that
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are being used to identify the malignant melanomas with increased specificity and
sensitivity [13]. These 4 probe set were selected as best for distinguishing benign nevi
from malignant melanoma [38, 39]. RREB1 also known as Ras-responsive element
binding protein 1 (RRE) and Raf responsive zinc finger protein is a transcription factor
that binds to RRE and leads to increased Ras/Raf activity. MYB is another transcription
factor. CCND1 is cyclin D1 proto oncogene which plays an important role in G1-S phase.
CEP6 is used as a control for the ploidy status for chromosome 6. When tested with these
4 genes in so many studies, they were able to distinguish benign from melanoma in most
of the cases, thus this 4 probe panel became significant in diagnosing the melanoma.
However FISH has its own limitations that it cannot detect smaller abnormalities in the
chromosome, cannot be used for screening the entire chromosomes and is loci specific
[40, 41]. Another cytogenetic technique, comparative genomic hybridization (CGH) has
become a useful technique since it can look into the entire genome to look for
abnormalities. CGH has been a very useful technique in cancer research [42] and in
diagnosing melanoma [43]. Even though it has the ability to distinguish the tumors it has
its own disadvantages of having very less resolution of 3-10 Mb [44] which means its
inability to detect smaller regions in copy number changes and certain chromosomal
regions involved in losses and gains [40] across the genome. So this lead to another
technique called array CGH with higher resolution to look into the entire genome to
analyze abnormalities on entire genome and/or chromosome of our interest. Array
comparative genomic hybridization (aCGH) can detect simultaneously single nucleotide
polymorphisms (SNP), is a DNA sequence variation occurring in which a single nucleotide (A,
T, C or G) in the genome or other shared sequence differs between members of a species or
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within the paired chromosomes. Copy number variations that have alterations of DNA

across the genome with more than normal number of segments of DNA (gene) either
deleted or amplified can also be detected in a single experiment. aCGH is a highly
specific, fast, and high throughput technique. It can be used to distinguish between
benign nevi and malignant melanoma by using FFPE tissues [45]. It can be used on
variety of sample types such as paraffin embedded [46], frozen [47], cell lines [48] ,
blood samples [49] and has major applications in cancer [50]. It has shown promising
results for diagnosing many cancers [50]. An important advantage is that it requires only
a minimum number of cells from FFPE tissue sections [45].

Because of its high resolution, array CGH is being used to identify the most frequent
genomic variants called SNP. SNPs can affect the function of genes and SNPs act as
biological markers in finding the genes involved with diseases [51]. Studies have shown
that the SNPs are useful in studying cancer [52, 53]. Benign nevi are associated with an
increased risk of melanoma [54]. Therefore it is important to look into both benign and
melanoma to find the actual SNPs associated with melanoma. Some of the genes that are
associated with SNPs and are involved in melanoma are BRAF [55], GNAQ [56],
GNA11 [57], PLA2G6, MTAP and IRF4[54]. We are interested in SNPs and genes that
are associated with melanoma.

Array CGH has its own limitations. It requires good quality and a sufficient quantity of
DNA to successfully hybridize to the microarrays.

Getting good quality DNA from

formalin fixed paraffin embedded tissues (FFPE) remains challenging. FFPE tissues are
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used as starting material in our research. Because it has many advantages such as stability
for decades [58], can be used for routine histopathologic diagnosis of diseases [58], easy
handling and especially used for downstream analysis [59] At the same time DNA
obtained from biopsied tissues are small and often irreplaceable. We have to extract DNA
by an efficient extraction method. While FFPE tissues are stable for decades [60], this
preservation presents significant challenges.

The process of fixation with formalin,

embedding and handling the tissues, should be done carefully in order to improve the
quality of the nucleic acids for molecular testing [61]. Formalin treatment cross-links
biological molecules such as DNA and proteins [61] so the nuclear material will get
trapped and prevent from breakage which later has to be reverse cross linked to retrieve
the nuclear material. Also, since longer nucleic acids like RNA and DNA, are fragmented
in the preservation process, it leads to poor performance in downstream analyses [62, 63].
To optimize utility of nucleic acids from FFPE specimens for aCGH, we must reverse
these cross links and avoid further degradation during the DNA extraction process.
Inefficient tissue rehydration results in poor reverse cross linking and thereby less quality
of DNA, so it is very important to rehydrate the tissue during paraffin removal. Several
previous studies have compared protocols for DNA extraction from FFPE tissues, with
varying results. Senguven et al. compared several variations on the CTAB method that
used CTAB to disrupt the cellular membranes and a hot alkali method that lyse the
genetic material with alkaline solution, and these both methods are compared with the
Qiagen FFPE DNA kit [64], a solid-phase extraction that uses silica gel membrane in the
spin column to trap the nucleic acids and eluted later with buffer. They found that the
Qiagen columns performed best, and that DNA yield became especially low in samples
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more than 50 years old. There is some controversy between laboratories, however, as
other studies have compared the Qiagen kit with phenol-chloroform. This is a liquidliquid extraction method separates the proteins in organic phase and DNA in the aqueous
phase. They found either the columns [65] or the phenol method [66] to be superior in
yield and amplifiability. Other methods less frequently used, not measured in our study
include the Maxwell 16 method by Promega (Mannheim, Germany). In this method, the
nucleic acids bound to magnetized silica particles and later eluted. This extraction method
was shown to perform well against other automated Qiagen kits [67], and the Chelex
bead method (Bio-Rad, Berkeley, California). This is an ion exchange resin that
inactivates the nucleases by removing magnesium and thus protects DNA for the PCR.
Chelex bead method has been used with some success in manual or automated
extractions from FFPE tissues [68]. A small number of studies have shown that the DNA
obtained by a recent sonication-based method called adaptive focused acoustics (AFA) is
more amenable to next generation sequencing than DNA from other methods, resulting in
greater coverage of the genome and facilitating easier assembly and alignment [69-71].
AFA is also a solid-phase extraction but it uses acoustic energy to de-paraffinize the
tissues. To our knowledge, ours is the first study to compare AFA for use in aCGH.
Here, we compared three different extraction methods: phenol-chloroform extraction,
commercial (Qiagen) column-based purification, and adaptive focused acoustic (AFA)
extraction, to see which works best to retrieve DNA for aCGH. Quantity and quality
measures are considered for each extraction method. Nanodrop concentrations which are
based on spectophotometric absorbance at 260 nm are measured and also the 260/230 and
260/280 ratios were measured to check the purity of the samples. Since Nanodrop
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concentrations are not accurate because the absorbance at 260 nm can measure not just
dsDNA, so we measured qubit concentrations, since fluorescent dye in qubit only binds
to the dsDNA and gives accurate concentrations of our samples. Next, we performed
RAPD PCR that amplifies DNA template randomly to see whether the DNA in our
samples are degraded or not by doing gel electrophoresis. Finally we measured RAPD
PCR failure rates in each method, samples that have not shown enough amplicon length
(< 300base pair length) are considered as failure and will be removed.
Once we got good quality of DNA then samples were hybridized them on to the
microarrays successfully. These microarray data were analyzed using Genotyping
Console (GTC) for genotyping analysis to get SNPs list. Then the SNPs were filtered and
analyzed using Partek Genomics Suite (PGS). Once got the SNPs and associated genes
list, used Ingenuity Pathway Analysis (IPA) to confirm our findings with the curated
literature in IPA about the genes and SNPs known to be involved with melanoma. We
found total of 8 genes along with the associated SNPs. Along with 8 genes known to be
involved in melanoma, their associated novel SNPs were identified in genes that are
known

to

be

involved
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in

melanoma.

II. METHODS AND MATERIALS

Specimen Collection and preparation:
After IRB review, the FFPE tissue blocks were collected from a national
dermatopathology laboratory (Dermatopathology Laboratory of Central States, DLCS,
Dayton, OH). They were stored in a temperature-controlled room. First we retrieved the
clinical data and health records of the patients using laboratory information management
software (Intellipath) at DLCS. The biopsy specimens collected are from 2007 and 2004,
making them 8 or 11 years old. Patients ranged in age from 16 to 75 years. Based on the
clinical data, we selected specimens that are unambiguously benign or melanoma and of
sufficient size to not exhaust the tissue block during analysis.
10µm thickness sections were taken from FFPE tissue blocks using a microtome with
disposable blades at DLCS. To avoid contamination between blocks, care was taken by
wearing gloves and using new blades for every specimen. Sections were slightly warmed
in the water bath to facilitate mounting onto slides. The slides were then air dried
overnight. The first and last slides were kept for H&E staining and examined under
microscope to confirm that the sections on the slides have the region of interest (benign
melanocytic nevi or melanoma cellular material). The tissues in the sections were
scrapped off avoiding as much paraffin as possible using sterile scalpel blades and
collected into 1.5 ml centrifuge tubes for extracting the DNA. The number of sections
and the amount of tissue taken were dependent on the extraction method (see below).
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DNA isolation from FFPE tissues:
For DNA isolation three extraction methods were used: Qiagen QIAamp DNA FFPE
tissue kit, phenol-chloroform isoamyl alcohol extraction and Adaptive Focused Acoustics
(AFA) - based extraction using the Covaris truXTRAC FFPE DNA kit.
Qiagen method:
The protocol suggested by Qiagen QIAamp DNA FFPE tissue kit (QIAGEN
GmbH, D-40724 Hilden) is as follows:
1. Using a scalpel, trim excess paraffin off the sample block.
2. Cut up to 8 sections 5–10 µm thick. If the sample surface has been
exposed to air, discard the first 2–3 sections.
3. Immediately place the sections in a 1.5 or 2 ml micro centrifuge tube
and add 1 ml xylene to the sample. Close the lid and vortex vigorously for
10 sec.
4. Centrifuge at full speed for 2 min at room temperature (15–25°C).
5. Remove the supernatant by pipetting. Do not remove any of the pellet.
6. Add 1 ml ethanol (96–100%) to the pellet, and mix by vortexing. The
ethanol extracts residual xylene from the sample.
7. Centrifuge at full speed for 2 min at room temperature.

11

8. Remove the supernatant by pipetting. Do not remove any of the pellet.
Carefully remove any residual ethanol using a fine pipet tip.
9. Open the tube and incubate at room temperature or up to 37°C.
Incubate for 10min or until all residual ethanol has evaporated.
10. Resuspend the pellet in 180 µl Buffer ATL. Add 20 µl proteinase K,
and mix by vortexing.
11. Incubate at 56°C for 1 h (or until the sample has been completely
lysed).
12. Incubate at 90°C for 1 h. The incubation at 90°C in Buffer ATL
partially reverses formaldehyde modification of nucleic acids. Longer
incubation times or higher incubation temperatures may result in more
fragmented DNA. If using only one heating block, leave the sample at
room temperature after the 56°C incubation until the heating block has
reached 90°C.
13. Briefly centrifuge the 1.5 ml tube to remove drops from the inside of
the lid. If RNA-free genomic DNA is required, add 2 µl RNase A (100
mg/ml) and incubate for 2 min at room temperature before continuing with
step 14. Allow the sample to cool to room temperature before adding
RNase A.
14. Add 200 µl Buffer AL to the sample, and mix thoroughly by
vortexing. Then add 200 µl ethanol (96–100%), and mix again thoroughly
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by vortexing. It is essential that the sample, Buffer AL, and ethanol are
mixed immediately and thoroughly by vortexing or pipetting to yield a
homogeneous solution. Buffer AL and ethanol can be premixed and added
together in one step to save time when processing multiple samples. A
white precipitate may form on addition of Buffer AL and ethanol. This
precipitate does not interfere with the QIAamp procedure.
15. Briefly centrifuge the 1.5 ml tube to remove drops from the inside of
the lid.
16. Carefully transfer the entire lysate to the QIAamp MinElute column
(in a 2 ml collection tube) without wetting the rim, close the lid, and
centrifuge at 6000 x g (8000rpm) for 1min.Place the QIAamp MinElute
column in a clean 2ml collection tube, and discard the collection tube
containing the flow-through. If the lysate has not completely passed
through the membrane after centrifugation, centrifuge again at a higher
speed until the QIAamp MinElute column is empty.
17. Carefully open the QIAamp MinElute column and add 500 µl Buffer
AW1 without wetting the rim. Close the lid and centrifuge at 6000 x g
(8000 rpm) for 1 min. Place the QIAamp MinElute column in a clean 2ml
collection tube, and discard the collection tube containing the flowthrough.
18. Carefully open the QIAamp MinElute column and add 500 µl Buffer
AW2 without wetting the rim. Close the lid and centrifuge at 6000 x g
13

(8000 rpm) for 1 min. Place the QIAamp MinElute column in a clean 2ml
collection tube, and discard the collection tube containing the flowthrough. Contact between the QIAamp MinElute column and the flowthrough should be avoided. Some centrifuge rotors may vibrate upon
deceleration, resulting in the flow-through, which contains ethanol,
coming into contact with the QIAamp MinElute column. Take care when
removing the QIAamp MinElute column and collection tube from the
rotor, so that low-through does not come into contact with the QIAamp
MinElute column.
19. Centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min to dry the
membrane completely. This step is necessary, since ethanol carryover into
the eluate may interfere with some downstream applications.
20. Place the QIAamp MinElute column in a clean 1.5 ml micro centrifuge
tube (not provided), and discard the collection tube containing the flowthrough. Carefully open the lid of the QIAamp MinElute column and
apply 20–100 µl Buffer ATE to the center of the membrane.
Important: Ensure that Buffer ATE is equilibrated to room temperature. If
using small elution volumes (<50 µl), dispense Buffer ATE onto the
center of the membrane to ensure complete elution of bound DNA.
QIAamp MinElute columns provide flexibility in the choice of elution
volume. Choose a volume according to the requirements of the

14

downstream application. The volume of elute will be up to 5 µl less than
the volume of elution solution applied to the column.
21. Close the lid and incubate at room temperature for 1 min. Centrifuge at full speed
(20,000 x g; 14,000 rpm) for 1 min, incubating the QIAamp MinElute column loaded
with Buffer ATE for 5min at room temperature before centrifugation generally increases
DNA yield.
The original protocol for the Qiagen FFPE DNA Tissue kit, modified by previous student
in the lab (Sameep Naik), is as follows:
1. Took 10µm thickness sections and Incubate tissue sample at 60˚C in water bath for 30
minutes.
2. Wash the tissue in micro centrifuge tube with 1 ml of 100% xylene and vortex,
centrifuge at 20,000xg for 5 minutes, and then remove supernatant.
3. Wash tissue in 500µl of 100% ethanol, vortex and centrifuge at 20,000xg for 3 minutes
then remove supernatant.
4. Wash tissue in 500µlof 75% ethanol, vortex and centrifuge at 20,000xg for 3 minutes
then remove supernatant.
5. Wash tissue in 500µl of 50% ethanol, vortex and centrifuge at 20,000xg for 3 minutes
and then remove supernatant.
6. Allow tissue to dry before processing.
7. Add 300µl buffer ATL to dried tissue.
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8. Add 100µl proteinase K, mix by vortexing.
9. Incubate overnight (8-12 hours, never longer than 16 hours) at 56˚C.
10. Add 400µl buffer AL to the sample and mix by inversion.
11. Incubate at 70˚C for 10 minutes.
12. Add 400µl ethanol to the sample and mix by inversion.
13. Pipet mixture into DNeasy Mini Spin Column then centrifuge at 6000xg for 1 minute.
Discard the flow through.
14. Add 500µl wash buffer AW1, then centrifuge at 6000xg for 1 minute. Discard the
flow through.
15. Add 500µl wash buffer AW2 then centrifuge at 6000xg for 1 minute. Discard the
flow through.
16. Add 500µl wash buffer AW2 again, then centrifuge at 6000xg for 1 minute. Discard
the flow through.
17. Replace flow through tube with clean tube, then centrifuge at 20,000xg for 3 minutes
to remove any residual ethanol from the spin column.
18. Replace flow through tube with the clean micro centrifuge tube.
19. Add 100µl buffer ATE, incubate at room temperature for 5 minutes.
20. Centrifuge at 20,000xg for 1 minute.
We used the protocol of previous student but with some modifications as follows:
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1. Cut 24 FFPE sections of 10 µm thickness for each DNA extraction.
2. Incubate tissue samples in water bath at 60˚C for 30 minutes.
3. Wash tissues in micro centrifuge tube twice in 1 mL xylene, vortex and centrifuge at
20,000xg for 3 minutes each time.
4. Wash tissues in a descending concentration of ethanol (100, 75%, and then 50%), each
time vortex and centrifuge at 20,000xg for 3 minutes and then remove supernatant.
5. Allow tissues to dry in the micro centrifuge tubes completely before proceeding to next
step.
6. Add 300 L Qiagen buffer ATL plus 40 L proteinase K (20mg/mL, 5 PRIME Inc.,
Gaithersburg, MD, USA) to dried tissue and mix by vortexing, incubate overnight for
first 24 hours.
7. Then add an additional 30 L proteinase K at 24 hours and another 30 L at 48 hours.
8.

After 72 hours digestion, add 400µl buffer AL to the sample, mix by inversion (never
vortex after overnight incubation).

9. Incubate at 70˚C for 10 minutes.
10. Add 400µl ethanol to the sample and mix by inversion.
11. Pipet sample mixture into were Qiagen DNeasy Mini Spin Columns, then centrifuge at
6000xg for 1 minute. Discard the flow through.
12. Add 500µl wash buffers AW1 and AW2 one by one, each time centrifuge at 6000g for 1
minute and discard the flow through.
13. Add 500µl wash buffer AW2 again, then centrifuge at 6000xg for 1 minute. Discard the
flow through.
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14. Replace flow through tube with clean tube, then centrifuge at 20,000xg for 3 minutes to
remove any residual ethanol from the spin column.
15. Replace flow through tube with the clean micro centrifuge tube.
16. Add 100µl buffer ATE, incubate at room temperature for 5 minutes.
17. Centrifuge at 20,000xg for 1 minute.
Phenol-chloroform-isoamyl alcohol extraction method:
Phenol-chloroform-isoamyl alcohol 25:24:1 (Fisher Scientific, Fair Lawn, New Jersey,
USA) was used as described in Isola et al. The protocol is as follows:
1. Twenty to thirty 5µ- sections were deparaffinized in eppendorf tubes (2
x 1 ml xylene for 10 minutes each and 2 x 1 ml 100% ethanol for 10
minutes each).2. After air drying at room temperature, samples were
suspended in 1 ml DNA extraction buffer (0.3 mg/ml proteinase K
(Sigma, St. Louis, MO), 100 mmol/L NaCI, 10 mmol/L Tris-HCI pH 8, 25
mmol/L EDTA pH 8, and 0.5% sodium dodecyl sulfate) and were
incubated with shaking at 55˚C overnight.
3. Additional proteinase-K (10µl from 20 mg/ml stock solution) was
added 24 hours and 48 hours later for a total incubation time of 72 hours.
4. A 500µl sample mixed with 500 µl phenol chloroform isoamyl
(Amresco, Solon, OH) was incubated at room temperature for 10 minutes
and centrifuged.
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5. DNA in the top layer was collected and precipitated with 250 µl of 7.5
mol/L ammonium acetate and 1 ml of ice-cold 100% ethanol.
6. DNA was pelleted by centrifugation (14,000 rpm for 20 minutes).
7. Glycogen (0.1 mg/ml; Sigma) was added before centrifugation as a
carrier to increase the volume of the pellet.
8. DNA was dissolved overnight in 20 to 40 µl of TE buffer (10 mmol/L
Tris, 1 mmol/L EDTA).
We used the same protocol but with some modifications:
1. 24 sections of 10 m thickness were used from each FFPE sample. FFPE sections were
scraped off of the air-dried slides using sterile scalpel blades and collected into 1.5 mL
micro centrifuge tubes.
2. Add 1ml of xylene to each tube, vortex and incubate for 10 min, centrifuge for 5 min at
20,000 x g. Discard the supernatant.
3. Repeat the above step again.
4. Add 1ml of 100% ethanol, vortex, incubate for 10 min, centrifuge for 3 min at 20,000 x
g. Discard the supernatant.
5. Repeat the above step.
6. Add 1ml of 75% ethanol, vortex, incubate for 10 min, centrifuge for 3 min at 20,000 x g.
Discard the supernatant.
7. Air dry the tubes at room temperature by inverting them on a tissue.
8. Add 985 µl of DNA extraction buffer and 15µl of proteinase k.
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9. Keep tubes now on water bath shaking incubator at 57˚C (control temperature) or at 70˚C
(Stat temperature).Adjust the speed to 3-3½ rpm.
10. Keep checking the water level in the shaker regularly.
11. Add 10µl proteinase k to each tube after 24 hours and vortex very lightly.
12. Add 10µl proteinase k to each tube after 48 hours and vortex very lightly.
13. After 72 hours take out the tubes and keep them at 95˚C for 40 min and bring them to
room temperature.
14. Add 500µl of each tube and 500µl of phenol chloroform to one tube (shake the
chloroform) and vortex.
15. Centrifuge at 20,000g for 1 min.
16. 2 layers will be formed in each tube, flip each tube for 5 sec and let them sit for 5 min at
room temperature.
17. Centrifuge at 20,000rcf for 10 min at 4˚C.
18. Transfer the top aqueous layer that has DNA to new tube.
19. Add chloroform approximately the amount of DNA the new tube has (for 100ul of DNA
amount add 100ul of chloroform), flip the tube, incubate for 5 min at room temperature
and centrifuge at 20,000rcf for 10 min.
20. Using pipette take put the top layer, put them in new tube. Discard the organic solvent by
dumping them in the container in SASH.
21. Add 1ml of ice cold ethanol to each tube and then add 250µl of ammonium acetate
22. Keep the tubes in -80˚C for about an hour and centrifuge at 14,000 rpm
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DNA Purification:
1. Wash the pellet by adding 500µl 70% ethanol, invert several times, and spin at maximum
speed at 4˚C for 5 min.
2. Aspirate carefully. Dry the pellet completely(~5-10min)
3. Pre-warm the TE buffer (Tris 10Mm, EDTA 1Mm pH8.0) at 55˚C and add 40µl buffer to
each tube.
4. Incubate at room temperature for overnight.
Adaptive focused acoustics:
The third extraction method is adaptive focused acoustics (AFA) technology. This was
performed using FFPE tissues with 10 m thickness for 8-10 sections. The extraction was
performed according to the protocol suggested by Covaris (Woburn, MA, USA) in the
truXTRAC FFPE DNA kit. Slides were warmed on a heat block to 37 °C for 30 seconds.
FFPE tissue was then scraped from the slides, avoiding paraffin, using Covaris
SectionPicks. Sections were collected into Screw-Cap microTUBES by using FFPE
SectionPicks provided by Covaris. AFA was performed per manufacturer’s instructions
(“protocol C”) on a Covaris M220 Focused-Ultrasonicator. The protocol is as follows:
1. Open microTUBE Screw-Cap, add 100 µl Tissue SDS Buffer into
microTUBE and load FFPE tissue (section or core). Affix Screw-Cap
back in place.
2. Process the sample using the settings provided in the protocol to dissociate
the paraffin while simultaneously rehydrating the tissue. During the AFA
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process it is normal for the solution to turn milky white as the paraffin is
emulsified.

Paraffin removal and tissue rehydration settings

Proteinase K mixing settings
3. Open Screw-Cap microTUBE, add 20 µl of Proteinase K solution to the
sample and affix Screw-Cap back in place.
4.

Process the sample using the settings provided to properly mix Proteinase
K with the sample.

5. Protein digestion at 56°C. Insert the required number of Heat Block
microTUBE Adapters into a Heat Block and set the temperature to 56°C.
6.

Load the microTUBE into the adapter once the heat block has reached its
set point.

7.

An incubation time of 1 hour at 56°C is sufficient for sections 10 µm or
less in thickness; 12-hour (i.e. overnight) incubation should be used for
larger samples, such as 25 µm sections and cores. If the digestion is
incomplete after 12 hours, add 20 µl of Proteinase K solution, mix, and
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incubate for 1 more hour. Here homogenized tissue was digested for 2
hours instead of 1 hour in proteinase K provided by Covaris kit.
8.

Incubate the samples at 80°C for 1 hour to reverse formaldehyde
crosslinks.

9.

Insert the required number of Heat Block microTUBE Adapters into a
Heat Block and set the temperature to 80°C. Load the microTUBE into the
adapter once the heat block has reached its set point.

10. If using the same heat block for both the 56°C & 80°C incubations, the
microTUBE should be stored at room temperature until the heat block
reaches 80°C.
11. Transfer the sample to a clean 1.5 ml micro centrifuge tube.
Optional: The sample can be treated with RNase A to remove RNA before
DNA purification. Add 5µl of RNase A solution and incubate for 5
minutes at room temperature.
Then DNA purification is as follows:
Set heat block to 70°C and preheat the required volume of Buffer BE in a
1.5mL microfuge tube: (number of samples x 100 µl x 1.1)
1. Add 140 µl Buffer B1 to your sample and vortex thoroughly.
2. Add 160 µl ethanol (>96%) to the sample and vortex thoroughly.
3. Centrifuge at 10,000 x g for 2 minutes at room temperature. After
centrifugation much of the paraffin will have formed a white layer,
floating on top of the liquid.
4. Place a Purification Column into a provided Collection Tube.
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5. While holding the sample tube at about the same angle as in the rotor,
use a pipette to slowly recover the liquid layer, and transfer to the column.
Transfer of a small amount of paraffin particles to the column is
acceptable and will not interfere with the DNA purification.
6. Spin the assembly at 11,000 x g for 1 minute.
7. Discard the flow-through and place the Column back in the Collection
Tube.
8. 1 st wash: Add 500 µl Buffer BW. Spin the assembly at 11,000 x g for 1
minute.
9. Discard the flow-through and place the Column back in the Collection
Tube.
10. 2 nd wash: Add 600 µl Buffer B5. Spin the assembly at 11,000 x g for
1 minute.
11. Discard the flow-through and place the column in a new Collection
Tube
12. Dry column: Spin the assembly at 11,000 x g for 1 minute.
13. Elute DNA - 1 st step: Place the Purification Column into a new 1.5 ml
microfuge tube and add 50 µl pre-warmed Buffer BE (70 °C) to the center
of the column. Incubate at room temperature for 3 minutes. Spin the
assembly at 11,000 x g for 1 minute.
14. Elute DNA – 2 nd step: Add a second aliquot of 50 µl pre-warmed
Buffer BE. Incubate again at room temperature for 3 minutes. Spin the
assembly at 11,000 x g for 1 minute.
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15. DNA is eluted in 100 µl Buffer BE.
We followed the same protocol but we changed the paraffin removal treatment time from
300sec to 510sec .For this extraction method the DNA was concentrated by speedvac
without heat in order to get enough concentration for the SNP 6.0 protocol.
Quality control:
A Nanodrop spectrophotometer was used to quantify DNA concentration as well as
determine the A260/A230 and A260/A280 ratios. Clean the Nanodrop first by 1.5 µl water
and then by 1.5 µl of buffer, the type of buffer depends on which extraction method the
DNA sample was eluted. Now load 1.5 µl of DNA sample on to the Nanodrop to check
the concentration and ratios.
Qubit:
For a more accurate quantitation, the Qubit® dsDNA BR Assay Kit (Thermo Fisher
Scientific, Waltham, MA) was used to check the concentrations of dsDNA for all
samples.
We followed the manufacturer’s protocol. The protocol is as follows:
1. Set up the required number of 0.5-mL tubes for standards and samples.
The Qubit® dsDNA BR Assay requires 2 standards.
Note: Use only thin-wall, clear, 0.5-mL PCR tubes. Acceptable tubes
include Qubit® assay tubes.
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2. Label the tube lids. Note: Do not label the side of the tube as this could
interfere with the sample read. Label the lid of each standard tube
correctly. Calibration of the Qubit® fluorometer requires the standards to
be inserted into the instrument in the right order.
3. Prepare the Qubit® working solution by diluting the Qubit® dsDNA
BR Reagent 1:200 in Qubit® dsDNA BR Buffer. Use a clean plastic tube
each time you prepare Qubit® working solution. Do not mix the working
solution in a glass container. Note: The final volume in each tube must be
200 µL. Each standard tube requires 190 µL of Qubit® working solution,
and each sample tube requires anywhere from 180–199 µL. Prepare
sufficient Qubit® working solution to accommodate all standards and
samples. For example, for 8 samples, prepare enough working solution for
the samples and 2 standards: ~200 µL per tube in 10 tubes yields 2 mL of
working solution (10 µL of Qubit® reagent plus 1990 µL of Qubit®
buffer).
4. Add 190 µL of Qubit® working solution to each of the tubes used for
standards.
5. Add 10 µL of each Qubit® standard to the appropriate tube, then mix
by vortexing 2–3 seconds. Be careful not to create bubbles. Note: Careful
pipetting is critical to ensure that exactly 10 µL of each Qubit® standard is
added to 190 µL of Qubit® working solution.
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6. Add Qubit® working solution to individual assay tubes so that the final
volume in each tube after adding sample is 200 µL. Note: Your sample
can be anywhere from 1–20 µL. Add a corresponding volume of Qubit®
working solution to each assay tube: anywhere from 180–199 µL.
7. Add each sample to the assay tubes containing the correct volume of
Qubit® working solution, then mix by vortexing 2–3 seconds. The final
volume in each tube should be 200 µL.
8. Allow all tubes to incubate at room temperature for 2 minutes.
Reading standards and samples procedure are as follows:
1. On the Home screen of the Qubit® 2.0 Fluorometer, press DNA, then
select dsDNA Broad Range as the assay type. The “Standards” screen is
displayed. Note: If you have already performed a calibration for the
selected assay, the instrument prompts you to choose between reading new
standards and running samples using the previous calibration. If you want
to use the previous calibration, press No and skip to step 5. Otherwise,
continue with step 2.
2. On the Standards screen, press Yes to read the standards.
3. Insert the tube containing Standard #1 into the sample chamber, close
the lid, then press Read. When the reading is complete (~3 seconds),
remove Standard #1.
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4. Insert the tube containing Standard #2 into the sample chamber, close
the lid, then press Read. When the reading is complete, remove Standard
#2. When the calibration is complete, the instrument displays the Sample
screen.
5. Insert a sample tube into the sample chamber, close the lid, then press Read. When the
reading is complete (~3 seconds), remove the sample tube. The instrument displays the
results on the Sample screen. The value displayed corresponds to the concentration after
your sample was diluted into the assay tube. To find the concentration of your original
sample, you can record this value and perform the calculation yourself or the instrument
can perform this calculation for you. Repeat step 5 until all samples have been read.

Electrophoresis:
Genomic DNA fragment sizes were first estimated by agarose gel electrophoresis of 250
ng DNA using 1 % agarose gels (90 mM Tris–borate, 2 mM EDTA, 1% agarose).
Samples were stained using SYBR safe (Life Technologies) and ran at ~120 volts for
about an hour and visualized under GE ImageQuant LAS-3000 camera (GE Healthcare
Life Sciences, Piscataway, NJ, USA). The Jurkat genomic DNA (Thermo Scientific) was
used as a positive control for comparison and Lambda DNA-HINDIII Digest (New
England Biolabs) ladder which is 23,130bp was used for looking and comparing the size
of the genomic DNA.
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RAPD PCR:
Samples with visible DNA fragments as large as 23,000 base pairs (bp) were processed
further by randomly amplified polymorphic DNA PCR (RAPD-PCR) to determine which
sample is ideal for SNP 6.0 by looking at the amplifiability of each sample that have high
molecular weight amplicons. Non-specific primers and PCR conditions were used to
produce multiple amplicons from each sample.
RAPD-PCR reactions were carried out in a 20 µL volume containing 25 ng DNA and
using 10µl of GoTaq 2X Green Master Mix (Promega, Madison, WI USA) that contain
bacterially derived Taq DNA polymerase, reaction buffers at optimal concentrations for
efficient amplification of DNA templates by PCR, dNTPs, MgCl₂ and Go Taq® Green
Master Mix contains two dyes (blue and yellow) that allow monitoring of progress during
electrophoresis. PCR was performed in 0.2mL tubes in a GeneAmp PCR System 9700
thermocycler (Life Technologies, Carlsbad, CA, USA).
Primers used for RAPD-PCR were generated by Eurofins MWG Operon Inc (Huntsville,
AL, USA). Sequences for the primer pairs and cycling parameters were as follows: 5’AATCGGGCTG-3’ and 5’-GAAACGGGTG-3’, denaturation for 94˚C for 2.5 minutes,
then 45 cycles of amplification (1 minute at 94˚C, 1 minute at 55˚C and 2 minutes at
72˚C) then final extension for 7 minutes at 72˚C and holding at 4˚C; or 5’TGTGCCCAGTGAAGACTCAG-3’ and 5’- GAGTGAGCGGAGAGGGAACT-3’, 45
cycles of 94° C denaturation for 1 minute, 35° C amplification for 1 minute, and 72° C
extension for 2 minute and holding at 4˚C . PCR products were resolved on 3% TBE
agarose plus SYBR Safe dye (Life Technologies). In order to see which DNA extraction
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method will give enough amount of DNA which is around 500bp amplicon length for
SNP 6.0 protocol, gels were imaged with a GE ImageQuant LAS-3000 camera (GE
Healthcare Life Sciences, Piscataway, NJ, USA) and visualization was carried out as
described under Electrophoresis above.
Microarrays:
A larger set of 63 skin biopsy specimens (21 benign and 42 melanoma) that includes a
subset of nine extracted by AFA method and the remaining were extracted by Qiagen
method were first quantified by Nanodrop, Qubit and RAPD PCR, then processed and
hybridized to Affymetrix SNP6.0 microarrays. 0.5 µg of genomic DNA was processed
using the SNP 6.0 protocol and microarrays suggested by Affymetrix (Affymetrix, Santa
Clara, CA, USA) with some modifications to the standard protocol.
The original protocol is in Affymetrix Genome-Wide Human SNP Nsp/Sty 6.0 User
Guide which is as follows;
Day 1
1. Sty1 Digestion
2. Sty 1 ligation
3. Sty 1 PCR
Day 2
1. Nsp 1 digestion
2. Nsp 1 ligation
3. Nsp 1 PCR
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Day 3
1. PCR QC 2% Agarose Gel
2. PCR Purification by Iso propanol method
Day 4
1. Fragmentation
2. Fragmentation QC 4% Agarose gel
3. Labelling
Day 5
1. Hybridization of genomic DNA to microarray chips
Day 6
1. Fluidics wash of microarray chips
2. Scan the microarray chips
Some modifications done by previous student (Sameep Naik) are as follows:
The input amount of DNA was increased from 250ng per restriction enzyme (Nsp1 and
Sty1) to 500ng each. The number of PCR reactions were doubled from the suggested 3
for Sty1 and 4 for Nsp1 to 6 for Sty1 and 8 for Nsp1. It is important to note that the
number of reactions was increased; the number of cycles in each reaction remained the
same. The additional PCR reactions were combined as in the standard protocol. PCR
cleanup was performed using isopropanol extraction (refer to Affymetrix User Bulletin 2:
Improvements to step 7 of the SNP Assay 6.0, PCR cleanup, using an isopropanol
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precipitation method, P/N 702968 Rev. 1). Hybridization, washing, staining and lastly
scanning of the arrays which are controlled by Affymetrix Genechip Command Console
(AGCC) software, these steps were followed by the manufacturer’s protocol. Microarray
data (CEL, ARR and CHP files) are obtained for every sample when microarray chips
were scanned using the GeneChip Scanner 3000 7G using AGCC software
Data Analysis:
27 benign melanocytic lesions were extracted with each extraction method and these
three methods were compared and determined statistically by looking into Nanodrop
concentration (ng/section), 260/280 and 260/230 ratios, Qubit concentration (ng/section),
RAPD-PCR amplicon lengths, and PCR failure rates using a two-tailed paired student’s ttest of the mean and standard error.
The CEL files obtained were processed in Affymetrix Power Tools (APT) provided by
Affymetrix. Contrast Quality Control (CQC) which is the primary QC for Genome wide
Human SNP Array 6.0 was calculated and compared to restriction fragment sizes (for
Nsp1 and Sty1) to evaluate microarrays to see which PCR products were successfully
hybridized to the array. It measures the SNP signals and estimate how well they resolve
into three genotype clusters. A subset of probes were used to measure the differences in
contrast distributions for both homozygote and heterozygote genotypes. CQC will assign
a call rate to each fragment length depending on how successfully they hybridized to the
array. Optimally a CQC value ≥ 0.4 [72] is considered a successful hybridization of
genomic DNA fragment to the arrays.
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Genotyping Console Software:
The CEL files of 63 specimens (21 benign and 42 melanoma samples) were added in the
genotyping console and performed primary intensity quality control (QC) for each
sample. Intensity QC contains QC metrics, In/Out bounds, #CEL/CHP files, ARR files of
all samples. First, samples were filtered based on CQC that has a default threshold value
of greater than or equal to 0.4 which is showed by bounds whether the samples met QC
value or not. Only samples that passed this QC should be used for genotyping analysis.
The genotyping console uses algorithm called BIRDSEED V2, it is a SNP genotyping
algorithm that runs on the Affymetrix SNP 6.0 platform. Birdseed uses a customized
Expectation-Maximization (EM) algorithm to fit two-dimensional Gaussians to SNP data,
producing genotypes and confidence scores for every individual at every SNP. Since it is
a clustering algorithm, it runs on so many samples at the same time (50 or more). The
batch genotyping results that has sample QC metrics like CQC will be shown in CHP
summary table. This table generates the batch CHP files. These output format files of
genotyping console can be used as input files in downstream applications like Partek
Genomics Suite (PGS) for further analysis. With the help of CHP summary table, SNPs
list can be generated by filtering the QC call rate with a default threshold of ≥ 90%. The
call rate is defined as the fraction of called SNPs per sample over the total number of
SNPs in the dataset. Any samples with SNP call rates below this threshold value are
omitted from the further analysis since these can cause false positive results. Once SNPs
list are created, we can export this list to PLINK statistical tool in the standard format
(PED and MAP) files.
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gPlink:
gPLINK has integration with PLINK which is a statistical tool for whole genome
association analysis. gPLINK is a java based program and is a graphical user interface
tool that uses most of the PLINK command operations. It is free software and can be
downloaded in this website: http://pngu.mgh.harvard.edu/purcell/plink/. The output files
of genotyping console (PED and MAP) are used as input files for gPLINK.
A PED file is a white-space (space or tab) delimited file where each line
represents one individual and the first six columns are mandatory and in
the order ‘Family ID’, ‘Individual ID’, ‘Paternal ID’, ‘Maternal ID’, ‘Sex
(1 = male, 2 = female, 0 = missing)’and ‘Phenotype (1 = unaffected, 2 =
affected, 0 = missing)’. The subsequent columns denote genotypes which
can be any character (e.g. 1,2,3,4 or A, C, G, T). 0 denotes a missing
genotype. Each SNP must have two alleles (i.e. both alleles are either
present or absent). The order of SNPs in the PED file is given in the MAP
file, where each line denotes a single marker and the four white-space
separated columns are ‘Chromosome (1-22, X, Y or 0 for unplaced)’,
‘Marker name (typically a “rs_” number)’, ‘Genetic distance in Morgans
(this can be fixed to 0)’ and ‘Base-pair position (bp units)’[73]. These two
files are converted to binary PED files (BED) to save space and time. This
BED file has FAM file that store the pedigree/phenotype information and
create an extended MAP file (.bim) which contains information about the
allele names. So this creates (by default): plink.bed (binary file, genotype
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information), plink.fam (first six columns of mydata.ped ), plink.bim
(extended MAP file: two extra columns = allele names) [74].
Sample based QC: The first step is to load the Bed files of both benign and melanoma
samples in gPLINK and then filter them by excluding samples with too much missing
genotype data which can lead to poor analysis. The default threshold value of 0.1(10%) is
used which means the samples will be excluded if they have more than 10% missing
genotype data.
SNP based QC: After sample QC we apply SNP-based QC for each SNP within each
sample. First, SNPs with a rate of missing genotype data ≥ 0.05(5%) are excluded from
further analysis. This is to remove any SNP with more than 5% missing genotype data,
because if they don’t have genotyping data it can lead to false negative, false positive
results. Next SNPs with a minor allele frequency  0.05 are similarly excluded. This is a
frequency at which a least minor allele occurs in a population. Any SNP with less than
5% is removed, this filter is applied because SNPs with MAF greater than 5% are said to
be involved with diseases. Finally, we exclude SNPs with Hardy Weinberg (HW)
deviations observed from expected p-values of 0.01 or greater. HW equilibrium states
that allele and genotype frequencies in a population will remain constant from generation
to generation in the absence of other evolutionary influences. Removing SNPs with
extreme deviation from equilibrium. All these QC metrics were performed with
recommended threshold values and the SNPs which did not pass these values were
removed.
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Partek Genomics Suite (PGS):
PGS is a software which is a user-interface, easy to use, has built-in workflows for a
variety of genomic workflows that supports Next generation Sequencing, Microarray data
and

qPCR

platforms.

We

can

download

the

software

at

their

website

http://www.partek.com/updates , but need license to access it. For studying SNPs, we
used Association workflow in the PGS. This workflow requires genotyping calls such as
.CHP files from Affymetrix SNP 6.0 Protocol as input for analysis. We performed
Sample and SNP based QC for our data and then association analysis for our samples.
The steps were followed as PGS User Association Workflow guide suggested:
The Sample QC option will invoke the sample QC spreadsheet, which
shows one sample per row.
1.

The rate of missing genotype calls for each sample is given in the
Sample NC Rate column. The rate is determined by dividing the
number of no calls (NC) by the total number of genotypes in the
sample and an unusually high number in this column indicates that the
overall genotyping quality in the sample is poor. As a rough guide, one
can tolerate a NC rate of up to 5%.

2. The Sample Heterozygosity Rate can also be used as a quality
indicator. As a rule of a thumb, you might want to reconsider the
samples with the heterozygosity rate which falls out of the interval
mean ± 3 × standard deviations of all the samples. To calculate the
mean and standard deviation for the heterozygosity rate of the samples
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please use Stat > Descriptive > Column Statistics… and select mean
and standard deviation from the list of available Candidate Measures.
3. After removing the samples which did not pass the sample QC criteria
you can proceed to the next QC step, Hardy-Weinberg equilibrium,
which is essentially QA/QC on SNP level. The resulting spreadsheet
(HWE) features one SNP per row. The difference between the
observed and expected frequencies of each allele at each locus (or
SNP) are tested by χ2 test (Chi^2 and p-value (Chi^2)).
4. Frequencies of both alleles are provided in the columns A Freq and B
Freq, while the minor allele frequency (MAF) corresponds to the one
with lower frequency. The remaining three columns contain the no-call
frequency (NC Freq), heterozygous frequency (Het Freq), and
homozygous frequency (Homoz Freq) at the given locus.
5.

Depending on the annotation provided by the array vendor, it may be
possible to annotate the SNPs with exact base calls at each locus.
Please right-click on a column header and select Insert Annotation. In
the Add Rows/Columns to Spreadsheet dialog, please tick mark the
Allele A and Allele B boxes. Two new columns will be added to the
HWE spreadsheet and will contain the genotype of each allele.

6. At this stage, the following two filters may be considered: 1. A SNP
no-call rate should be less than 5%. 2. Minor allele frequency of a SNP
should be greater than 5%.
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7.

After that, have removed the SNPs that are not in Hardy Weinberg
equilibrium. For that purpose, a multiple testing correction should be
applied to the exact p-value: the cut-off p-value after the correction
equals 0.05 / (number of SNPs left after 1st and 2nd filter) (in the other
words, Bonferroni’s correction). The filtering can be performed by the
interactive filter (the icon), to first filter in the SNPs with the NC
frequency less than 0.05, and then to filter in the SNPs with MAF
greater than 0.05. Please note that the effects of the interactive filter
are additive.

8. However, in order to proceed to the next step of the workflow, the
changes (i.e. filtering in of SNPs which met the chosen QA/QC
criteria) have to be applied to the parent spreadsheet; the same SNPs
need to be filtered in.
9.

To do that please select the parent spreadsheet (in this example this is
the one with 17 samples on rows) and then choose Filter > Filter
Columns > Filter Columns Based on a List… In the Filter Columns on
Spreadsheet dialog, please set the Filter based on spreadsheet to the
spreadsheet containing the final SNPs and set the Key column to SNP.

Association Analysis:
After filtering samples and SNPs, now we perform association analysis
using chi-square test. The steps are as follows:
10. To set the phenotype (categorical variable) this will be tested for
association with the SNPs. In the other words, the allele/genotype
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frequencies as specified by the model (please see the discussion
below) will be compared between the categories.
11. By setting the Column variable to Tissue, in this example, one will test
the association of the SNPs with cancer.
12. The model section allows for specification of the statistical model.
Allele: frequencies of alleles (A vs. B) are compared across the
categories of the selected variable (i.e. phenotype).
13. Significant p-value indicates that the allele/genotype frequencies are
different between the categories of the selected variable, i.e. that an
association exists between the genotype and the phenotype.
14. In the present example χ2 statistic was used to assess the difference in
allele frequencies (allele model) between the normal and cancer
samples. The resulting spreadsheet (Chi-square) shows one SNP per
row.
15. PGS provides the value the associated p-value (chisq p-value) for each
SNP.
This p-value along with the genes associated with the filtered SNPs are saved as tab
limited text and is exported to IPA.
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Ingenuity Pathway Analysis (IPA) is a web-based functional analysis tool for
comprehensive genomic data. Quickly gain knowledge on the genes by browsing
categorized and curated publication. To download this software go to their website
http://www.ingenuity.com/products/ipa, which is available for 7 day free trail and have to
sign up before you want to download. An email will be sent to your email address which
has the link to download the IPA software. Download and install IPA. First import the
genes list from PGS.
1. When you hit “run the core analyses” it will show up all the diseases that the genes
associated with them.
2. Click on the “cancer” disease and then once a new tab opens where it shows all the
cancers, click on the “melanoma” cancer.
3. List of genes and their associated SNPs will show up based on the literature and
databases integrated with IPA.

These genes and SNPs can be checked with the list
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obtained in PGS

III. RESULTS AND DISCUSSION

A total of 27 dermal nevi specimens, preserved in formalin and embedded with paraffin
(FFPE), were selected from DLCS. These FFPE block tissues can be stored for a very
long time and their accreditation requirements can be fulfilled easily, because of this we
were interested in FFPE tissue blocks. The College of American Pathologists (CAP)
Commission on Laboratory Accreditation at the present time needs FFPE blocks to be
retained for 10 years [75, 76] and also the surgical pathology records. These FFPE tissue
blocks can be used for research purposes as long as 1) HIPAA requirements for patient
privacy are followed 2) the diagnostic laboratory keeps enough tissue for diagnostic
purposes, 3) the diagnostic laboratory has facilities to return any FFPE material
remaining after use in research and 4) the demands of applicable institutional review
boards (IRB), state and local laws are adhered to. Additionally, CAP currently suggests
retaining the archived materials beyond 10 years if possible mainly because of the
demand for these specimens for several research areas including cancer research as
biomarkers are developing. The clinical data of these specimens, such as patient age,
diagnosis and the age of these blocks and their storage at the room temperature for an
average period of 8.67 years and average age was 38 years are shown in Table 1.There
was enough material found on these specimens for the three extraction methods. For
DNA extraction, the sections were cut sufficiently from each sample according to each
method (see Materials and Methods). The first and last slides were stained with
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hematoxylin and eosin (H&E) and observed under microscope (Figure 1) and used for
further analysis only if the slides from beginning to the end that were cut have at least
50% of tumors present in each section of sample. Sometimes when we cut we exhaust
the tumor tissue in the middle and when we get to the last section we may not have
tumor.

Figure 1: H&E staining for the first and last slides of tissues

Examining the H&E sections on either side of our analyzed sections tells us whether the
samples we take for further analysis contain sufficient tumor cells, and allows us to
prevent complete depletion of any specimen.

Sample
number
1
2
3
4
5

Patient
age
30
25
16
35
38

Sex
F
M
M
F
M

Specimen
age
(years)
8
8
8
8
8

Clinical notes
Biopsy, nose, left side dermal nevus
Biopsy, scalp, right post dermal nevus
Biopsy, abdomen left dermal nevus
Biopsy, back, left center dermal nevus
Biopsy, scalp dermal nevus
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6
7
8
9
10

21
26
32
31
69

M
M
F
M
F

8
8
8
8
8

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Average:

40
44
22
56
47
35
29
34
44
75
36
60
16
41
16
35
74
38.04

F
F
F
M
F
F
F
F
F
F
M
F
F
F
F
M
F

8
8
8
8
8
8
8
8
8
8
8
11
11
11
11
11
11
8.67

Biopsy, back right middle dermal nevus
Biopsy, abdomen dermal nevus
Biopsy, cheek, right dermal nevus
Biopsy, axilla, right dermal nevus
Biopsy, back, right upper dermal nevus
Biopsy, axillary area. Anterior nevus lipomatosus
superficialis
Biopsy, calf, left post dermal nevus
Biopsy, chest, left lateral neurotized dermal nevus
Biopsy, cheek, left intradermal melanocytic nevus
Biopsy, axilla, left dermal nevus
Biopsy, chest dermal nevus
Biopsy, back, midline lower neurotized dermal nevus
Biopsy, deltoid left ant dermal nevus
Biopsy, lip, left upper dermal nevus
Biopsy, knee, left medial dermal nevus
Biopsy, axilla right dermal nevus
Biopsy, back dermal nevus
Biopsy, back, left upper dermal nevus
Biopsy, forehead, right neurotized dermal nevus
Biopsy, back, inferior lower dermal nevus
Excision, malar, left dermal nevus
Biopsy, back, left upper dermal nevus

Table 1: Details of the patients used in this study

Aim 1:
In spite of the accessibility of archived specimens, the procedure of fixation leads to the
difficulty of using the nucleic acids from these FFPE tissue blocks [77]. So as to
overcome these hurdles, it is essential to use effective extraction methods for the nucleic
acids. For this, we extracted DNA and compared the three methods from the same 27
FFPE tissues by looking into the quantification measures like total yield, A260/A230 and
A260/A280 ratios, and the purity of DNA. This can be analyzed by looking into the
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“amplifiability” of each DNA sample by performing RAPD-PCR to see if the
contaminants such as xylene, ethanol and salts are inhibiting the PCR reaction. We found
that the quality and quantity of extracted DNA can remarkably affect the downstream
processes.
Using the three extraction methods phenol-chloroform isoamyl alcohol, Qiagencommercial kit and AFA (Adaptive Focused Acoustic), 27 samples were extracted. So
many literature suggested different deparaffinization timings and protein digestion times
[59, 78-81]. Increasing protein digestion time from overnight to 72 hours can increase the
DNA yield according to some studies[77, 79] ,so in the Qiagen QIAamp DNA FFPE
Tissue Kit method, the samples were digested with proteinase K for 72 hours instead of
overnight digestion in order to get better yield of the DNA. In phenol chloroform isoamyl
alcohol method, protein digestion was performed for 72 hours to increase the yield. After
protein digestion, the samples were incubated at 94˚C for about 40 minutes to reverse
crosslinks. The higher the temperature and more incubation time will be better for
reversible cross-linking[82],but if the DNA is not cross-linked can cause fragmentation,
affect downstream applications [83-85] and also to melt any paraffin that is left in the
sample [86]. In order to precipitate the DNA in the samples, they were either kept at 80˚C for about 1 hour or can keep at -20˚C for about an overnight[59] ,depending on
whether you want to proceed the extraction method immediately or later. The glycogen
used in this method is to increase the size of the pellets in our samples, but it is avoided
since our samples had enough pellet size. Xylene is used in both phenol chloroform and
column based extraction methods to remove paraffin. Even though xylene can remove
paraffin efficiently[87], any residuals of this can cause low 260/230 ratios and affect
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downstream processes like PCR[88]. So it is better to avoid xylene in any extraction
process. On the other hand, the AFA does not need xylene or any other organic solvents
to remove paraffin. But the deparaffinization takes place in the AFA machine by creating
focused bursts of ultra-sonic acoustic energy; this causes hydrodynamic shear stress,
emulsification of paraffin and tissue rehydration at the same time. Because of no xylene
and automatic removal of paraffin by acoustic energy in this method, the amplicon length
in the RAPD PCR (Figure 2 and Table 2) is increased for the AFA samples when
compared to other two methods.
Measures

Phenol

Column

AFA

DNA (ng)/section
(Qubit)

106.2  33.1

264.3  35.4

134.6  18.1

DNA (ng)/section
(Nanodrop)

702.1 200.2

716  116.1

453.8  53.9

A260/A280

1.94  0.02

2.04  0.03

1.90  0.02

A260/A230

1.71  0.18

1.71  0.12

1.75  0.43

Max. amplicon (bp)

346.7  24.1

347.4  21.4

401.9  10.2

PCR Failure Rate

25.93%

22.22%

3.70%

Table 2: Summary of the three Methods Comparison for 27 samples
showing the QC measures
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Figure 2: RAPD PCR comparison for the three methods. All the four samples (1, 2, 3, and 4)
were compared with negative and positive control (PC; Jurkat DNA) and these same
samples were extracted using three different methods

The deparaffinization time in AFA method was increased from 300 sec to 500 sec
because initially the paraffin was not removed properly with 300 sec time and so to
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improve this step we increased the time. The main factors of these three extraction
methods are compared and given in Table 3.
Factors

AFA

Qiagen

PCI

Number of sections
(10µm thickness)

~10

~24

~24

Protein Digestion
time

~2 hours

~ 72 hours

~ 72 hours

Chemicals

No Organic
solvents

Organic
solvents

Organic
solvents

Table 3: Comparison of factors for the three methods
After extracting the genomic DNA of 27 samples with three methods, the best way to
qualify the genomic DNA is to look at the quantification and assessment of dsDNA [89,
90] for downstream analysis. This qualification can be done by checking the
contaminants (ethanol, phenol) in the samples with Nanodrop by looking into 260/280,
260/230 ratios. Then look into Qubit concentrations for more accurate concentration of
DNA. This is because the dye in the Qubit assay only binds to the double stranded DNA
whereas Nanodrop shows high concentration, since it measures absorption at different
wavelengths like 230nm, 260nm. For the nucleic acids the absorption takes at 260nm,
and so it measures absorption to oligos, single nucleotides, ssRNA rather than just to
dsDNA. The 260/280, 260/230, Nanodrop and Qubit concentrations are shown in Table
2. The DNA yield per section for Qubit was also shown in Table 2, Figure 3 and for
Nanodrop is shown in Table 2, Figure 4. This is calculated based on the elution volume
and the number of sections used per sample.
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Figure 3: DNA yield per section using Qubit
readings

The column samples showed better yield per section (p<10-4). Even though the
column sample showed better yield per section, it is also important to consider the
sample purity, reasonable PCR amplicon sizes and less PCR failure rates for using
these samples in SNP genotyping, FISH, comparative genomic hybridization and
other techniques. Since DNA purity is important to consider for downstream
applications, we looked the 260/280 and 260/230 ratios. The 260/280 ratio (Table
2, Figure 4) is the first measure to look for purity of the nucleic acid and it should
have ~1.8 value, all the three methods slightly have around 1.8 .260/230 (Table 2,
Figure 5) is the second measure for the purity of the nucleic acid and anything
around 2 shows the nucleic acids are pure. All three methods have A260/A230
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values of approximately 2.0, which is the optimum value of pure DNA

Figure 4: A260/280 ratios comparisons of three methods

Figure 5: A260/230 ratios comparisons of three methods
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To see the size range of the genomic DNA they were separated by 1% agarose gel
electrophoresis. For comparison we took the same 4 samples that are extracted with three
methods (Figure 6).

Figure 6: Genomic DNA comparison of three methods

Total amount of the genomic DNA range in the gel is almost similar which shows that the
three methods worked the same way. Since RAPD-PCR is one of the good ways to
quantify our samples, we now looked at the amplicon size of the 4 samples in Figure and
for 27 samples in Table 2. Of all the AFA had showed higher amplicon length compared
to other methods(Figure 7, p 0.04), this could be because of not using xylene that can
interfere with the DNA and can lead to poor PCR analysis and also the PCR failure rates
was low (3.70%) for AFA compared to the other two methods ( Table 2). Eliminating the
contaminants that are carried over during purification process is measured by the rate of
“PCR failure” (Table 2).
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Figure 7: Maximum Amplicon Length in RAPD PCR of three methods

When RAPD-PCR showed amplicons size of less than 300 bp in length, we did not use
those samples as it anticipates poor performance in the downstream PCR [91]. The
failure rates were around 25% by phenol-chloroform and around 22% by columns. On the
other hand, only one of 27 samples (3.7%) failed by AFA.
Aim 2: After extracting good quality of DNA with AFA method from benign FFPE
specimens, we used a Qubit fluorometer to determine DNA concentration. Since the
concentrations were less in Qubit we used a speed vac to concentrate the DNA. First, by
adding distilled water to the each sample to bring up the concentration to as close to
500ng/µl for each Sty and Nsp reactions in digestion and ligation process and one of the
advantage of using speed vac is that it will evaporate any leftover solvents like ethanol to
avoid carryover contamination. Then the samples were processed and hybridized to the
SNP 6.0 array comparative genomic hybridization (aCGH) microarrays. Some studies
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have shown that aCGH works well with FFPE specimens [47, 92] for analyzing the
tumor tissues [93-95] [96]. Also aCGH is helpful in distinguishing the malignant
melanoma from benign cases [45, 97-99] that are ambiguous since distinguishing them
can be difficult for the pathologists. Many factors like the age of FFPE tissue block,
storage, and also the quality of the DNA obtained from the FFPE tissues can affect the
downstream applications like Array CGH.

In the SNP 6.0 protocol, we performed QC

steps at two stages to see how qualitatively our AFA samples look. One after we perform
PCR for these AFA samples and this is shown in Figure 8 Affymetrix suggests to have
the

PCR

products

ranged

in

between

200

and

1100

bp

length[72].

Figure 8: Post PCR gel image in SNP 6.0 Protocol, 5 Sty and Nsp samples were
compared with the positive and negative controls

In the 4% agarose gel above the Sty and Nsp samples were in between the range
suggested by Affymetrix. So we checked the concentrations and purity of the AFA
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samples using Nanodrop .The DNA quantity was sufficient enough for all samples which
is around 3500 bp that is suggested by Affymetrix SNP 6.0 protocol and the purity of the
samples were also within range (Table 4).
Sample ID

Nanodrop Concentration

260\280

260\230

(ng\µl)

Ratio

Ratio

B282

5241.4

1.59

1.87

B283

5380.3

1.47

1.73

B285

3258.1

1.92

2.23

B286

4688.6

1.79

2.09

B287

3962.5

1.87

2.17

Table 4: PCR products of AFA samples showing their Nanodrop
concentrations and ratios within the range of SNP 6.0 protocol

After the first QC, we performed the fragmentation step using the PCR to fragment the
PCR products so that these small fragments can successfully hybridize to the arrays.
Affymetrix SNP 6.0 protocol says that the fragments should be less than 180 bp length to
successfully hybridize to the arrays. The samples were run on 4% Agarose gel to assess
the fragment size of the samples (Figure 9). All of the samples were fragmented in
between 100 and 200 bp.
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Figure 9: Fragmentation of PCR products on 4% Agarose Gel
for 4 samples

(We judged that the quantity of the DNA within the 100-200 bp range was probably
sufficient for hybridization, but this could have been further fragmented by repeating
fragmentation step for about 30 minutes or could have done this step three times each
reaction for 10 minutes rather than one reaction for 30 minutes to increase the DNase I
activity [63]. Rather than over-fragment the DNA, it was utilized as it was, and the end
results validated this decision.)

The fragmented samples were hybridized onto the

microarrays, and these microarrays were stained and washed if any fragments that were
not hybridized will be washed out. The microarrays were scanned using GeneChip
Scanner by Affymetrix and CEL files were obtained.
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Microarray Analysis: 9 AFA samples have been able to pass the QC steps in the SNP
6.0 protocol (PCR and fragmentation steps) i.e.; they have showed enough amplicon
length, concentrations and fragmented with ≤ 200bp of length. We used these AFA
samples along with the column samples to do next steps. Once CEL files are obtained we
further proceeded with microarray analysis by comparing 63 specimens of both columns
(54) and AFA (9) samples. The details of these 63 specimens are given in Table 5.
#

Sample

Age at
Diagnosis

Sex

Location

Clark's
level

Type

77

Year of
the
sample
2008

1

M07

Male

Right Arm

IV

T10
T12
T15

80
75

2005
2005
2005

Male
Male
Female

Forehead
Upper Back

IV
IV/V

5
6
7
8

T17
M18
T19
T20

40
60
-

2006
2007
2007
2007

Male
Male
Female
Female

Back
Left Leg
Elbow

IV
IV
IV

9

T23

81

2008

Male

IV

10

M27

93

2001

Male

Left
Auricular
Right Groin

11
12
13

M28
M30
M31

60
63

2007
2011
2008

Female
Male
Female

IV
IV

14

M33

76

2008

Female

Left Leg
Right
Forearm
Right Cheek

15

M50

57

2010

Male

Left Arm

IV

16

M54

45

2012

Female

Left Back

IV

17
18

M56
M58

60
66

2012
2011

Male
Male

Left Shin
Right Cheek

IV

19

M59

77

2011

Male

Right Elbow

IV

20

M64

27

2011

Female

Right Neck

IV

SUPERFICIAL SPREADING
TYPE
MALIGNANT MELANOMA
DESMOPLASTIC TYPE
SUPERFICIAL SPREADING
TYPE
MALIGNANT MELANOMA
MALIGNANT MELANOMA
NODULAR SPITZOID TYPE
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
NODULAR MALIGNANT
MELANOMA
NODULAR SPITZOID TYPE
MALIGNANT MELANOMA
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
ULCERATED NODULAR
MALIGNANT MELANOMA
SPITZOID TYPE
POORLY-DIFFERENTIATED
CARCINOMA!!!
INVASIVE MALIGNANT
MELANOMA
POSTERIOR INVASIVE
POLYPOID MALIGNANT
MELANOMA

2
3
4

55

IV

IV

21

M74

69

2010

Male

Left Temple

IV

22

M75

74

2010

Male

Left Neck

IV

23

M76

67

2010

Female

Right Back

IV

24

M77

53

2010

Male

Right Arm

IV

25
26

M84
M86

54

2009

Female
Female

IV

27

M98

72

2005

Male

28
29

M107
M111

80
48

2005
2005

Male
Female

30
31

M113
M116

40
74

2007
2007

Male
Female

Anterior
Thigh
Right
Shoulder
Forehead
Right
Forearm
Back
Right Arm

32

M130

63

2001

Male

Back

IV

33

M131

45

2001

Female

Left Arm

III

34
35
36
37

M132
M136
M137
M139

75
40
85
87

2001
2001
2001
2001

Male
Female
Female
Male

Right Chest
Upper Back
Right Cheek
Right Cheek

III-IV
III-IV
IV/V
V

38

M147

90

2002

Male

Left Back

IV

39

M148

55

2002

Female

Middle Back

II/III

40

M173

28

2008

Female

III

41

M174

42

2008

Male

42

M191

75

2001

Male

Left
Shoulder
Right
Pretibial
Left Back

43
44

NT06
NT07

34
44

2010
2010

Male
Female

45
46
47
48
49
50
51
52

NT12
B15
B27
B29
B30
B31
B47
B51

19
39
35
34
44
27
62

2010
2011
2011
2011
2011
2011
2011

Male
Female
Male
Male
Female
Male
Female
Female

Right Arm
Right
Buttock
Left Back
Left Neck
Left Flank
Right Neck
Right Groin
Right Back
Right
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III
IV
V
IV
II

SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
Malignant Melanoma with
vertical Growth
NODULAR MALIGNANT
MELANOMA
MALIGNANT MELANOMA
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
DESMOPLASTIC TYPE
NODULAR VARIANT

-

Malignant melanoma
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
DESMOPLASTIC TYPE
NODULAR TYPE
Malignant melanoma
CONSISTENT WITH THE
LENTIGO MALIGNA
MELANOMA SUBTYPE
SUPERFICIAL SPREADING
TYPE
SUPERFICIAL SPREADING
TYPE
INVASIVE SPITZOID
MALIGNANT MELANOMA
SUPERFICIAL SPREADING
TYPE
MELANOMA WITH
REGRESSION
DERMAL NEVUS
DERMAL NEVUS

-

DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS

III
IV

53
54

B52
B53_3

48
75

2011
2011

Female
Female

55
56
57
58
59
60

B254
B267
B272
B279
B282
B283

34
33
38
52
41
14

2007
2013
2013
2013
2013
2013

Female
Female
Female
Female
Female
Female

61
62
63

B285
B286
B287

16
21
60

2013
2013
2013

Female
Male
Female

Eyebrow
Left Neck
Left
Shoulder
Left Deltoid
Right Back
Right Back
Right Neck
Right
Shoulder
Right Back
Right Neck

-

DERMAL NEVUS
DERMAL NEVUS

-

DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS

-

DERMAL NEVUS
DERMAL NEVUS
DERMAL NEVUS

Table 5: Details of the 63 specimens

However, we did not use phenol samples even though they have good amplicon sizes in
the RAPD-PCR, they did not have sufficient amplicon length in the PCR, also the
concentrations were lower than 3000 ng\µl in the SNP 6.0 protocol. Using these CEL
files of these 63 specimens we did fragment length analysis by using Affymetrix Power
Tools (APT). APT analyzes the microarrays and assigns a call rate to every probe
depending on how successfully they hybridized to the microarray. Probes are sorted by
the size of the restriction fragment on which they occur. If any piece of region within the
restriction sites is missing then this region will also be missing in the samples that are
hybridized to the arrays. Any fragment of genomic DNA that is hybridized successfully
should have at least a contrast QC of 0.4. The Contrast QC captures the ability of an
experiment to resolve SNP signals into three genotype clusters. Here APT measures
contrast QC and we compared both AFA and column restriction fragment sizes of Nsp1
and Sty1 (Figure 10). Any fragment size showing below 0.4 threshold of CQC shows that
the samples have poor quality. AFA showed largest fragment size of 400 bp in Sty and
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500 bp in Nsp compared to the column samples. This APT analysis tells about the quality
of the DNA, the more range of fragments present per sample the better the data it will
have and can increase the yield of downstream analysis. Even though AFA showed better
fragment sizes, they still have missing fragments above 500 bp. This could be because of
the starting material (FFPE tissue) quality or samples could have not hybridized properly
to the arrays.

Figure 10: aCGH APT Fragment Length Analysis contrast QC
comparison
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Aim 3:
All 63 specimens ( including benign and melanocytic nevi) were hybridized on to the
Affymetrix SNP 6.0 microarrays were analyzed in Genotyping Console (GTC) by
Affymetrix, gPLINK, and Partek Genomics Suite (PGS) to perform association analysis.
The 63 CEL files that were obtained after the scanning of microarray chips were opened
in Genotyping Console for genotyping analysis. Before performing genotyping, we
checked the QC of the samples. The overall quality of samples were tested with contrast
QC (CQC) algorithm with a threshold value of ≥0.4.We use this because it is the default
CQC value established by Affymetrix for Genome-Wide Human SNP 6.0 array samples.
The Contrast QC captures the ability of an experiment to resolve SNP signals into three
genotype clusters. It uses a static set of 10,000 randomly chosen SNP 6.0 SNPs (Figure
11 taken from GTC 4.1 user manual); measuring the difference between peaks in contrast
distribution produced by homozygote genotypes, and the valleys they share with the
heterozygote peak, and takes the smaller of the two values. In poor quality experiments
the homozygote peaks are not well-resolved from the heterozygote peak and the
difference values approach zero.
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Figure 11: Distribution of Contrast Values. The X axis is the Contrast Value about which
a bin of size 0.02 is centered. The Y axis is the % of SNPs (10000 random autosomal GW
6 SNPs) whose Contrast values fall within the bin. Contrast = sinh[K*(AB)/(A+B)]/sinh(K)], K=2, A and B are the summary values for probes covering the A and B
alleles, respectively [1].

Samples passing the contrast QC threshold should show “In bounds” for
each sample but all of our samples were “out of bounds” which means
they have <0.4 value. Not every SNP is generated by both the StyI and
NspI enzymes but some will have the SNPs with just one enzyme set. This
issue can be solved by contrast QC. So this Contrast QC values are
calculated for contrast distributions produced by a static set of 20K
randomly chosen SNPs on NspI fragments and a static set of 20K
randomly chosen SNPs on StyI fragments. These are called Contrast QC
(NspI) and Contrast QC (StyI), respectively. If the absolute difference
between these two values is greater than two, this is evidence that that a
sample may have worked properly with one enzyme set, but not with the
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other, and the Contrast QC value is adjusted to zero to reflect this
problem.
Even though if the samples are “out of bounds” or did not pass the threshold value we
can still consider the samples for further analysis (genotyping) if we keep in mind the
limitations of the study.
Genotyping analysis identifies genomics variations (SNPs) in the genomes of different
individuals. For analyzing SNPs in our samples we performed genotyping analysis. The
genotyping results display CHP summary statistics where it shows call rate of all
samples. The call rate of a sample is defined as the fraction of the number of SNPs called
out of all SNPs on the array. Our samples had an average call rate of 61.73%. The higher
the call rate the better we can avoid the false positive/false negatives in the analysis. A
good call rate can be greater than 90%. This low call rate could be because of some of
the samples did not pass the intensity QC which tells that some samples are missing the
expected SNPs on the probes. The genotyping calls of 909,622 SNPs for every sample
were determined using the Birdseed V2 genotype calling algorithm, which is in the
Affymetrix GTC software. The samples were assigned genotypes and then SNPs were
removed when they have low call rate of ≤90%, any SNP above or equal to 90% means
they are good enough for the analysis. The low call rate in our experiment indicates that
more than 10% of the SNPs for our samples have missing genotype data. This can cause
serious analysis complications downstream. With the help of CHP files, a SNPs list was
created for SNPs with call rates ≥90% in our samples. The number of SNPs before and
after filtering is summarized in Table 5. The flow chart shows the steps in the genotyping
console (Figure 10). In order to use these SNPs for further analysis, this list is exported to
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gPLINK in the format of PED and MAP files. The PED file has information about the
sample like Family ID, Individual ID, phenotype and gender whereas MAP file contains
information about marker ID (rs...), chromosome number and base pair position. The
quality control (QC) measures are an important step for studying genotype data of
genome-wide association studies (GWAS) to reduce false findings.

63 CEL files

Sample QC≥0.4
(using CQC Algorithm)
Sample
call rate≥90%

Genotyping Analysis
using BIRDSEED V2
Algorithm

CHP file Summary for
every sample

Exported to Partek
Genomics Suite (PGS)

SNP QC:
call rate≥90%

Filtered SNPs list

Exported to gPLINK in
PED and MAP file formats

Figure 12: Flow chart showing the QC steps for both
Samples and SNPs in GTC
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gPLINK
1. The PED and MAP files from GTC were first converted to BED files to bring the
information in these two format files together and save space. This BED file is first
filtered with recommended QC steps [73, 100]. The recommended SNP QC steps are
minor allele frequency, missingness rate, and Hardy Weinberg equilibrium. First, the
samples were filtered using missingness rate per individual (MIND) with a threshold of
0.1this is a good indicator of marker quality. This will remove the samples that have
more than 10% missing genotype data since more missing genotyping data leads to false
positive or false negative results [100]. But all of our samples have less than 10% missing
genotype data. Then we applied SNP based QC for every SNP in every individual. The
first SNP based QC step for SNPs is

minor allele frequency (MAF). This refers to

the frequency at which the least/ less abundant allele occurs in a given population. Any
SNP with a 5% or less minor allele frequency are removed. . We use MAF to remove
SNPs because the statistical power is very low to detect association for rare SNPs
(usually < 1% frequency), so it is better to remove these rare SNPs to avoid burden for
the analysis using the power of statistical tools [100] Next SNP based QC is the missing
rate per SNP (GENO) with a threshold of 0.05 is used to filter out some more SNPs. If
they have more than 5% missing genotype data that can increase the rate of false results.
A summary is provided in the Table 6 to show the total number of samples and SNPs
excluded and included after QC in the analysis.
2. SNPs were again filtered based on their Hardy Weinberg (HW) equilibrium. HW is a
model/law/theorem that states in a population, allele and genotype frequencies remain
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constant from generation to generation. The default threshold of 0.05 is used to filter out
SNPs.

Samples in study

SNPs in study

Before QC

After QC

Before QC

After QC

GTC

63

63

818245

319777

gPLINK

63

63

316244

107385

PGS

63

63

909622

107909

Table 6: This summarizes the number of SNPs and Samples filtered out after QC
steps in each statistical tool

Any SNPs that are deviated from this equilibrium are removed. any deviation from HWE
threshold shows that genotyping error happened and/or the controls having association
with the diseases [73].Explained with details about the HWE in PGS section.
A difficulty with gPLINK is any sample with “unknown gender” or “wrong gender” will
be removed from analysis since gPLINK considers this warning as an error. There are
some unknown genders in our samples. Also not every command in PLINK is available
in gPLINK like “gender check” to avoid the problem discussed above. PLINK/gPLINK
does not have proper contact in case if we want to ask any questions or have any
concerns. So as a new starter, it will take time to understand and interpret the results.
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Partek Genomics Suite (PGS):
In contrast to gPLINK, PGS does not remove any samples with unknown gender since it
takes the CHP summary files from GTC as the input, so we used PGS for further
analysis. Partek Genomics Suite is statistical analysis software that is user friendly, fast,
memory efficient, can work on large sets of data. It has several built-in workflows for
genomic data analysis like microarray and next generation sequencing workflows which
are easy to use. For our microarray data (CHP files) we used Microarray Association
workflow. Here we did sample and SNP-based QC steps. 63 Samples were filtered using
the no call rate (NC) for sample which means the rate of missing genotype calls for every
sample; it is a good way of assessing the sample quality. It has a default threshold of
≤5%, any sample with greater than 5% missing genotype data are removed since it can
cause false-positive and false-negative results and sample heterozygosity rate which is
the proportion of heterozygous genotypes for an individual [73] is an indicator of sample
DNA quality. the threshold for this rate is 0.908412 (max)–0.08313(min). The
heterozygosity rate of all samples should fall in the interval of mean±3* standard
deviation. Any sample out of this range is removed which means the samples have less
DNA quality [73] After this, we performed SNP based QC for every SNP in each sample.
Hardy Weinberg equilibrium, a SNP based QC step is a model which states that the
genotype and allele frequencies of a given population will be constant from generation to
next in the absence of other evolutionary influences. any deviation from HWE threshold
shows that genotyping error happened and/or the controls having association with the
diseases [73]. Usually HWE is tested first for controls because they will have similar
frequencies (allele and genotypes) than cases. The deviation can be determined by p65

value with a default threshold of > 0.05. p-value is used to test statistical hypothesis of
the observed sample results. Any SNP (in controls) with the observed p-value is less than
the expected p-value(0.05) is deviated from the HWE and thus excluded from the further
analysis [73]. This p-value is compared against the allele/genotype frequencies of
controls. Before performing the HWE QC step, we have to filter SNPs with No call NC
frequency for SNP which also gives a good assessment for every marker quality, is the
rate of missing genotype calls for every SNP; any SNP will be removed if it has greater
than 0.05 missing genotype data to avoid spurious results. Then the next QC step is minor
allele frequency (MAF). This refers to the frequency at which the least/ less abundant
allele occurs in a given population. The default threshold is greater than or equal to 0.05
which means any SNP with less than 0.05 MAF value is removed. We use MAF to
remove SNPs because the statistical power is very low to detect association for rare SNPs
(usually < 1% frequency), so it is better to remove these rare SNPs to avoid burden for
the analysis using the power of statistical tools [100] Once SNPs are removed with the
NC frequency, MAF and p-value of HWE, then we used an allelic chi-square test, this chi
square test is used to determine if there is any significant differences between observed
and expected allelic frequencies between cases melanomas) and controls (benign). In this
test, the SNPs were filtered again based on chi-square p-value using a cutoff p-value of
0.05. This p-value here is compared against cases and controls. Any SNP that has a pvalue greater than 0.05 was excluded from the analysis. Significant p-value (≤ 0.05)
shows that the allele frequencies are different between the cases and controls, which
mean there is an association exists between the allele or marker and the increased risk of
disease. Once we know that the samples (controls) are in HWE then we compare these
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controls to our cases. This test is just to see whether the samples have any poor
genotyping data, or have any inbreeding which can lead to biased comparison with other
population (cases). The parameters and thresholds are recommended by the PGS and
shown in Table 7. After these steps, we have the filtered SNPs list along with their
associated genes and chi square p-value. All the steps after using GTC are given in Figure
13 until we get significant SNPs.

Association
Analysis Tools
gPLINK

PGS

Sample QC & Thresholds SNPs QC & Thresholds
Missingness rate per Missingness rate per SNP≤5%
individual (MIND)≤ 10% Minor allele frequency(MAF)≥5%
Hardy
Weinberg
Equilibrium
(HWE)<5%
No call Frequency≤ No call frequency≤ 5%
5%Sample
Minor Allele Frequency(MAF)≥ 5%
Heterozygosity
rate= Chi-square p-value≤5%
0.908412
(max)–
0.08313(min)

Table 7: Statistical Tools with their parameters and thresholds
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63 CHP files from GTC
Sample QC

•

No call Frequency <= 5%
Sample Heterozygosity rate=
0.908412 (max)–0.08313(min)


After Sample QC
63 Samples
SNP QC




No call frequency≤ 5%
Minor Allele Frequency(MAF)≥5%
p-value ≤5% ( comparing the observed and
expected allele frequencies in controls
Chi Square Test (Allelic)

Chi square p –value≤0.05 (comparing the observed and
expected allele frequencies of SNPs in cases vs controls)

Before SNP QC

After SNP QC
909622
SNPs

107909 Filtered SNPs and
their Associated Genes
Exported to IPA
Only Genes with lowest chi-square
p-value (≥1.08E-22 & ≤5.30E-26)

Confirmed our findings with
curated databases and
literature in IPA

Found novel SNPs with
associated genes

Figure 13: Flowchart showing the steps in getting the filtered SNPs using PGS and
confirming them using IPA.
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IPA:
Ingenuity Pathway Analysis is a web based functional analysis tool for comprehensive
genomic data. We are interested in IPA because we want to explore the significance of
our findings. The genes list is being exported to Ingenuity Pathway Analysis (IPA) to
look whether the genes are known to be involved in cancer (especially melanoma) by
taking the genes with SNPs having the lowest associated p-values. By making the chisquare p-value even stricter - , filtered out the SNPs within the range of ≥1.08E-22 &
≤5.30E-26 and we

limited the analysis to 7,389 genes.

The SNPs and genes list from chi-

square allelic test are shown to be involved in the melanoma in the IPA based on several
databases like COSMIC, OMIM, Gene Ontology. These genes along with the SNPs
shown in IPA were compared back to the corresponding SNPs list we got from the chisquare test in the PGS to validate our findings. We found some genes and their associated
SNPs in the melanoma that are published in the literature are also present in our samples.
Some SNPs are found in both melanoma and benign samples and some are just in
melanoma. These SNPs in benign may predispose the benign to malignant melanoma
according to a literature [54]. These are listed in the Table 8.
SNP ID
rs1267649 (B&M)

GENES
BRAF

rs401681(M)

CLPTM1L

rs4845618(B&M)

IL6R

References
Meyer, P., C. Sergi, and C. Garbe,
Polymorphisms of the BRAF gene predispose
males to malignant melanoma
Stefanaki, I., et al., Replication and
predictive value of SNPs associated with
melanoma and pigmentation traits in a
Southern European case-control study
Gu, F., et al., Interleukin and interleukin
receptor
gene
polymorphisms
and
susceptibility to melanoma
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rs2736100(M)

TERT

rs9420907(B&M)

OBFC1

rs10757257(B&M)

MTAP

rs1015362(B&M)

ASIP

rs2284063(B&M)

PLA2G6

Iles, M.M., et al., The effect on melanoma
risk of genes previously associated with
telomere length
Iles, M.M., et al., The effect on melanoma
risk of genes previously associated with
telomere length
Kvaskoff, M., et al., Polymorphisms in
nevus-associated genes MTAP, PLA2G6, and
IRF4 and the risk of invasive cutaneous
melanoma
Maccioni, L., et al., Variants at chromosome
20 (ASIP locus) and melanoma risk. Int J
Cancer
Kvaskoff, M., et al., Polymorphisms in
nevus-associated genes MTAP, PLA2G6, and
IRF4 and the risk of invasive cutaneous
melanoma

Table 8: Genes and associated SNPs from IPA shown to be
involved in melanoma.

Some SNPs are found both in melanoma and benign (B&M) and some just found in
melanoma (M). CLPTM1L rs401681 are originally found to be in lung cancer as well as
melanoma [101] and TERT rs2736100 [102] both found in melanoma cases only whereas
BRAF rs1267649 [103] , IL6R rs4845618 [104], ASIP rs1015362 [105] , OBFC1
rs9420907 [102]. MTAP rs10757257 [54] and PLA2G6 rs2284063 [54] are found in both
benign nevi and melanoma.
CLPTM1L rs401681
CLPTM1L gene is associated with the cisplatin-induced apoptosis and it lies in the
cancer susceptibility locus on chromosome 5p 15.33, this is usually over expressed in the
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melanoma. rs401681 showing a significant p-value of 9.6*10-6 is found in this gene and
shown to be involved in many cancers like breast cancer [106], colorectal cancer
[106]and also melanoma [106].
TERT rs2736100
TERT is a telomerase reverse transcriptase and a ribonucleoprotein polymerase which
maintains telomerase ends located in chromosome 5. This telomerase functions as
cellular senescence and results in shortening of telomerase. This shortening of telomeres
are involved in the risk of cancer [102] especially melanoma [102] . rs2736100 having a
p-value of 0.02 and MAF value of 0.486 is located in the TERT gene and recently is
found to be involved in glioma [107], thyroid [107], bladder [107] cancer and found in
melanoma[107].
BRAF rs1267649
BRAF is a serine/threonine kinase in Ras/Raf/MAPK signal transduction pathway [108,
109] involved in the cell growth and is a proto oncogene. If mutated, the cell growth will
be continuous and leads to tumorigenesis. It is located on 7q34 chromosome with 190kb
of length. Recent studies have shown that this gene is mutated in the malignant
melanoma (66%). Also the BRAF mutation in benign can give rise to malignant
melanoma [110]. Meyer etal showed that rs1267649 is having a significant minor allele
frequency of ≥0.1 and is one of the non-coding SNPs present in intron 5 in the BRAF
gene. This SNP is shown to be involved in the increased risk of malignant melanoma in
their study.
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IL6R rs4845618
IL6R is a tumor growth inhibitor for early-stage of melanoma and a growth factor for the
tumor cells for advanced stage [104] patients with malignant melanoma when pretreated
with serum IL6 have a very short survival time [104]. It is present in chromosome 1. IL6
shows its activity when bound to IL6R which alters gene expression. Gu etal found that
IL6R along with rs4845618 is involved in the melanoma risk with a p-value in hardy
Weinberg equilibrium (HWE) is 1.04-2.84, is present in the intron region of the IL6R.
ASIP rs1015362
ASIP gene has a role in melanogenesis [111], when ASIP binds to MC1R it initiates
signaling and blocks the cAMP production. This leads to the down regulation of
eumelanogenesis (black/ brown pigments) and eventually increases pheomelanin
(yellow/red pigments). It is located in chromosome 20 and it has shown that the
rs1015362 has a MAF value of ≥0.1 and is located 110kb in the ASIP gene [105]. It is
most likely associated with the sun sensitivity like sunburns. So this SNP has an effect on
malignant melanoma.
OBFC1 rs9420907
OBFC1 is a subunit of alpha accessory factor that stimulates the activity of DNA
polymerase-alpha-primase; this enzyme initiates the DNA replication. Mutations in this
gene leads to cancer [112] . It is located in chromosome 10q24.33. This gene is present in
the longer telomere length and has shown to be involved in cancers like melanoma as we
as nevi and also breast cancer. rs9420907 which is present in the OBFC1 gene is
associated with melanoma with a significant p-value of 0.001.
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MTAP rs10757257
MTAP is a gene which plays a major role in polyamine metabolism and very important in
the salvage of adenine and methionine. The deficiency in this enzyme leads to cancer
because the p16 tumor suppressor gene and this MTAP gene are deleted together usually.
Located in 9p21 and 22q13 and is shown to be in the benign nevi and has a high risk of
melanoma [54] .
PLA2G6 rs2284063
PLA2G6 is a phospholipase A2 gene involved in the Ras signaling pathway. Mutations in
this gene or Ras signaling leads to the tumorigenesis. This is shown to be involved in
benign and the risk of melanoma [54]. rs2284063 is associated with this gene in benign
as we as melanoma [54]
Also in IPA we found some genes that are known to be involved in melanoma, but with
SNPs in our list which are different from the published cancer-associated SNPs. These
are not known to be involved in melanoma so far. So we expect that these SNPs may be
involved in melanoma (Table 9), or may be in linkage disequilibrium with cancerassociated SNPs.
GENES
ERC2

SNP ID(New)
rs732887 (B&M)

LRP1B

rs1372254 (B&M)

PDE1A

rs16823163 (B&M)
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SMAD3

rs9492489 (B&M)

CDH13

rs11860430 (M)

GRIN2B

rs10772713 (B&M)

CLCA1

rs1358826 (B&M)

GNAQ

rs17063991(B&M)

Table 9: Genes and new SNPs found in either
benign and nevi or just melanoma samples

Table 9 shows ERC2 [113], LRP1B[114], PDE1 [115], SMAD3 [116] repression of
CDH13 [117] , GRIN2B [118], CLCA1 [119], GNAQ [56]. All these genes are known to
be involved in melanoma. It may be that the SNPs associated with them are also involved
in melanoma.
ERC2 It is a regulator of neurotransmitter release located in chromosome 3p14.3.
Frequent transcriptional and genetic inactivation of ERC2 can be involved in
carcinogenesis [120] and in melanoma it is said to be deleted [113, 121] .rs732887 is
found in this gene with significant p-value of showing that it may have some association
with the melanoma [113].
LRP1B
This gene belongs to low density lipoprotein receptor gene family, located on 2q22.1
chromosome. They play an important role in the cell functions and development. This
gene is involved in the melanoma [114].
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PDE1
PDE1 is a phosphodiesterase calmodulin dependent protein, located on chromosome
2q32.1. The role of PDE1 gene is to degrade cGMP and cAMP. This gene regulates the
cell proliferation, if over expressed it leads to cancer [122] and melanoma [115].

SMAD3
This gene regulates the cell death, differentiation and proliferation. This helps in the
tumor growth in cancer. Repression of this enzyme leads to cancer [123, 124]. It is
located in chromosome 15q22.
CDH13
It is a protein coding gene that regulates the cell survival, proliferation and growth and
repression of this gene can cause tumor progression[125] and eventually to melanoma
[117].Located on 16q23.3 chromosome. It is indirectly involved in ERK signaling in the
melanoma [126]
GRIN2B
GRIN2B is a protein coding gene of glutamate receptor .Located on 12p13.1
chromosome. It has involvement in Ras signaling pathway [127]. GRIN2B is one of the
genes that cause melanoma when mutated according to a study [128].
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CLCA1
It is a protein coding gene located on 1p22.3. Plays an important role in cell adhesion.
Involved in basal cell adhesion and/or in squamous epithelia. It can act as a tumor
suppressor in colorectal and breast cancer. It has a key role for cell adhesion in the early
stages of lung metastasis [129]. It is a tumor suppressor gene but when mutated leads to
melanoma [130].
GNAQ
It is a Guanine nucleotide-binding protein which acts like transducer in various
transmembrane signaling pathways. Located on 9q21.2 chromosome. It has involvement
in MEK/MAPK and/or PI3K/AKT signaling indirectly [131]. The frequent somatic
mutation of this GNAQ cause melanoma [56] . It is a therapeutic biomarker for the uveal
melanoma [56].
However the SNPs associated with all these genes were so far not shown in the literature
that they involved in cancer/disease. But these SNPs have significant chi-square p-value
with in the range of ≥1.08E-22 & ≤5.30E-26, which indicates that they may be involved in
the disease. Further studies are needed however.
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• Generated 63 CEL files (21 benign & 42 melanoma)
SNP 6.0
hybridizati
on

APT

GTC

PGS

IPA

• Input : 63 CEL files
• Sample QC step : Figure 10

• Input : 63 CEL files
• Sample QC and generated genotypes (63 CHP files) :
Figure 12
• Output : 63 CHP files
• Input : 63 CHP files
• Sample and SNP QC followed by association analysis
between SNPs in both benign & melanoma and allele
frequency differences with p-value ≤0.05 : Figure 13
• Output: SNPs and genes list with p-values of both
benign and melanoma
• Input : Genes list filtered with strict p-value
(≤1.08E-22 & ≥5.30E-26)
• Core analysis
• Output : List of genes along with SNPs associaed
with melanoma (Table 8) that are already in
literature and also list of genes with new SNPs found
in melanoma (Table 9) which have to be validated

Figure 14: Flowchart showing sequential steps in analysis

Flowchart summarizes the sequential steps in filtering and analyzing the SNPs in both
benign and melanoma using different statistical tools.
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IIII. CONCLUSIONS

This part summarizes the findings and the problems we solved in the thesis work and
possible future directions.
In this thesis, we showed that the type of DNA extraction method does have an effect on
DNA quality, since getting DNA from FFPE tissues is always challenging even though it
has several advantages like stable for decades, can use very old FFPE blocks, vast
number of blocks available, easily accessible and easy handling and used especially in the
diagnosis of cancer. Column is a solid-phase extraction and phenol-chloroform method is
liquid-liquid extraction, both these methods require more sections of FFPE tissues, also
these methods de-paraffinize the tissues using organic solvents which can later interfere
with the DNA purification process and inhibit PCR reaction. On the other hand, AFA
which is solid-phase extraction that requires less number of tissue sections compared to
other two methods. This AFA method de-paraffinizes the tissues using acoustic energy
without any organic solvent xylene, which is commonly used for removing paraffin in
other two extraction methods. Our results show that the use of xylene is associated with
decreased amplicon length in PCR and increased RAPD PCR failure rate [132]. Any
sample shown less than 300 base pair length by RAPD PCR is considered as failure here.
It is very important to have greater than 300 base pair length of amplicon for downstream
analysis like array CGH [133] especially when using tumor biopsies of limited size.
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Although xylene-free extraction method have shown to be successful, they are not
standardized to reproducibility and safety guidelines for using clinically [134, 135].

Also in the AFA method, tissue rehydration takes place during the de-paraffinization
process that allows proper protein digestion and complete reverse-crosslinking,
supporting efficient purification of DNA [136].
The improved DNA quality from FFPE tissues is very important for the array CGH
analysis. One of the studies showed that the quality and quantity of FFPE DNA is
assessed by using Nanodrop, 260/230, 260/280 ratios and gel electrophoresis for looking
into genomic DNA for hybridizing successfully them to the microarrays. However they
did not perform PCR to know the degradation of FFPE DNA samples [137]. Here but in
our studies we did perform RAPD PCR along with Nanodrop, qubit and gel
electrophoresis to assess the quality of the samples. Of all the three extraction methods,
AFA method showed improvements in the FFPE DNA quality. Ours is the first study to
compare AFA with column and phenol methods.
AFA samples were performed with SNP 6.0 protocol, successfully hybridized to the
microarrays and were compared against the column samples, the phenol samples were
not used because they did not pass the initial QC steps in the SNP 6.0 protocol. The AFA
samples showed better initial quality control metrics like the optimum amplicon length in
the PCR, enough concentrations to proceed to next steps, good fragmentation length so
that they can hybridize to the microarrays successfully. These microarrays of AFA and
column samples when analyzed with the APT fragment length analysis, AFA samples
with fragments are hybridized better than column samples. This proves that extraction
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method of FFPE DNA does help in improving the quality of the DNA for hybridizing
onto the microarrays. The raw array data that was generated with these AFA samples
after SNP 6.0 protocol were genotyped using genotyping console and then the SNPs were
filtered and analyzed in Partek Genomics Suite. The SNPs with their genes from Partek
were confirmed in the Ingenuity pathway analysis tool. Some of the SNPs along with
their genes in our list were already shown in literature in Table 8 that they are involved in
the melanoma and some of them were shown in our benign samples. BRAF along with
rs1267649 is one of the most common genes and SNPs associated with melanoma is also
shown in our list. Also found some new SNPs in our list that were not shown to be
involved in the melanoma so far but the genes associated with these SNPs. Some of these
SNPs are found both in the melanoma and benign samples and some are just in the
melanoma. Benign nevi which are non-cancerous and not metastatic can give rise to
malignant melanoma when exposed to certain risk factors [54] whereas malignant
melanoma is a metastatic cancer. So these findings suggest that the new SNPs around the
known genes may also be involved in the melanoma and also the SNPs that are in the
benign nevi may give rise to the malignant melanoma. Recent findings showed that the
nevi, which are a risk factor for melanoma, have distinct patterns of genes and SNPs.
These findings may help in identifying the subsets of nevi that have distinct biological
features and the risk phenotypes in the individuals, however more studies have to be done
to confirm their findings [138].The project future directions include: Increase the size of
the samples, perform genotyping analysis separately for benign and melanoma with
normal samples. Find whether the SNPs found in our study are driver mutations or not by
linkage disequilibrium (LD) plots .Look into literature to find the function and also
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whether the genes we found in our data that are involved in melanoma are also involved
in other cancers. Perform Next Generation Sequencing (NGS) to generate genotype data.
SNPs obtained from clinical specimens that are statistically significant in malignant
melanoma and/or benign nevi, may represent the functional genes involved in melanoma.
Significant SNPs in benign nevi and/or melanoma that may predispose to malignant
melanoma can improve vigilance by encouraging detection of the melanoma in the early
stages and prognostic decisions.
.
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